<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Spinal Cord Med</journal-id><journal-id journal-id-type="iso-abbrev">J Spinal Cord Med</journal-id><journal-id journal-id-type="pmc-domain-id">350</journal-id><journal-id journal-id-type="pmc-domain">jspinalcordmed</journal-id><journal-title-group><journal-title>The Journal of Spinal Cord Medicine</journal-title></journal-title-group><issn pub-type="ppub">1079-0268</issn><issn pub-type="epub">2045-7723</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11864021</article-id><article-id pub-id-type="pmcid-ver">PMC11864021.1</article-id><article-id pub-id-type="pmcaid">11864021</article-id><article-id pub-id-type="pmcaiid">11864021</article-id><article-id pub-id-type="pmid">38466869</article-id><article-id pub-id-type="doi">10.1080/10790268.2024.2319384</article-id><article-id pub-id-type="publisher-id">2319384</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Prevalence of opioid use in adults with spinal cord injury: A systematic review and meta-analysis</article-title><alt-title alt-title-type="right-running-head"><italic toggle="yes">Borg</italic> et al. Prevalence of opioid use in adults with spinal cord injury</alt-title><alt-title alt-title-type="left-running-head"><italic toggle="yes">Borg</italic> et al. Prevalence of opioid use in adults with spinal cord injury</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1376-5320</contrib-id><name name-style="western"><surname>Borg</surname><given-names initials="SJ">Samantha J.</given-names></name><xref rid="AF1" ref-type="aff">1</xref><xref rid="AF2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1476-5744</contrib-id><name name-style="western"><surname>Cameron</surname><given-names initials="CM">Cate M.</given-names></name><xref rid="AF1" ref-type="aff">1</xref><xref rid="AF2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6037-5133</contrib-id><name name-style="western"><surname>Luetsch</surname><given-names initials="K">Karen</given-names></name><xref rid="AF3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7352-0291</contrib-id><name name-style="western"><surname>Rolley</surname><given-names initials="A">Adam</given-names></name><xref rid="AF1" ref-type="aff">1</xref><xref rid="AF2" ref-type="aff">2</xref><xref rid="AF4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8571-8315</contrib-id><name name-style="western"><surname>Geraghty</surname><given-names initials="T">Timothy</given-names></name><xref rid="AF5" ref-type="aff">5</xref><xref rid="AF6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1463-662X</contrib-id><name name-style="western"><surname>McPhail</surname><given-names initials="S">Steven</given-names></name><xref rid="AF1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0589-8521</contrib-id><name name-style="western"><surname>McCreanor</surname><given-names initials="V">Victoria</given-names></name><xref rid="AF7" ref-type="aff">7</xref><xref rid="AF8" ref-type="aff">8</xref></contrib><aff id="AF1"><label>1</label>Australian Centre for Health Services Innovation and Centre for Healthcare Transformation, School of Public Health and Social Work, <institution>Queensland University of Technology</institution>, <city>Kelvin Grove</city>, <country>Australia</country></aff><aff id="AF2"><label>2</label><institution>Jamieson Trauma Institute, Royal Brisbane and Women&#8217;s Hospital, Metro North Health</institution>, <city>Herston</city>, <country>Australia</country></aff><aff id="AF3"><label>3</label>School of Pharmacy, <institution>University of Queensland</institution>, <city>Woolloongabba</city>, <country>Australia</country></aff><aff id="AF4"><label>4</label><institution>Queensland Ambulance Service, Queensland Government Department of Health</institution>, <city>Brisbane</city>, <country>Australia</country></aff><aff id="AF5"><label>5</label>The Hopkins Centre, Menzies Health Institute Queensland, <institution>Griffith University</institution>, <city>Nathan</city>, <country>Australia</country></aff><aff id="AF6"><label>6</label>Department of Rehabilitation, <institution>Princess Alexandra Hospital, Metro South Health</institution>, <city>Woolloongabba</city>, <country>Australia</country></aff><aff id="AF7"><label>7</label><institution>Hunter Medical Research Institute</institution>, <city>New Lambton Heights</city>, <country>Australia</country></aff><aff id="AF8"><label>8</label><institution>University of Newcastle</institution>, <city>Newcastle</city>, <country>Australia</country></aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Samantha J. Borg, Australian Centre for Health Services Innovation and Centre for Healthcare Transformation, School of Public Health and Social Work, <institution>Queensland University of Technology</institution>, <city>Kelvin Grove</city>, <country>Australia</country>. Email: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="samantha.borg@hdr.qut.edu.au">samantha.borg@hdr.qut.edu.au</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>11</day><month>3</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>48</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">482993</issue-id><fpage seq="3">170</fpage><lpage>188</lpage><pub-history><event event-type="pmc-release"><date><day>11</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>27</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-04 04:25:30.160"><day>04</day><month>03</month><year>2025</year></date></event><event event-type="tagger"><event-desc>Nova techset</event-desc><date><day>18</day><month>2</month><year>2024</year></date></event><event event-type="final"><event-desc>Converted to JATS 1.2 by Nova Techset</event-desc><date><day>18</day><month>2</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Author(s). Published with license by Taylor &amp; Francis Group, LLC</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="YSCM_48_2319384.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="YSCM_48_2319384.pdf"/><abstract><sec><title>Objective</title><p>To determine the prevalence, reported harms and factors associated with opioid use among adults with spinal cord injury (SCI) living in the community.</p></sec><sec><title>Study design</title><p>Systematic review and meta-analysis.</p></sec><sec><title>Methods</title><p>Comprehensive literature searches were conducted in PubMed (MEDLINE), EMBASE, CINAHL, Web of Science and Scopus for articles published between 2000 and 2023. Risk of bias was assessed using a prevalence-specific tool. Random-effects meta-analyses were conducted to pool prevalence data for any context of opioids. Sensitivity and subgroup analyses were also performed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed, and the study protocol was registered via Prospero (CRD42022350768).</p></sec><sec><title>Results</title><p>Of the 4969 potential studies, 38 were included in the review. Fifty-three percent of studies had a low risk of bias, with a high risk of bias in 5% of studies. The pooled prevalence for the 38 studies included in the meta-analysis (total cohort size of 50,473) across any opioid context was 39% (95% confidence interval [CI], 32&#8211;47). High heterogeneity was evident, with a prediction interval twice as wide as the 95% CI (prediction interval, 7&#8211;84%). Mean or median opioid dose was unreported in 95% of studies. Opioid dose and factors related to opioids were also rarely explored in the SCI populations.</p></sec><sec><title>Conclusions</title><p>Results should be interpreted with caution based on the high heterogeneity and imprecise pooled prevalence of opioids. Contextual details including pain, cohort-specific injury characteristics and opioid dosage were inconsistently reported, indicating a clear need for additional studies in a population at greater risk of experiencing opioid-related adverse effects.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Adverse risks</kwd><kwd>Prescription drugs</kwd><kwd>Efficacy</kwd><kwd>Opioid analgesics</kwd><kwd>Spinal cord injuries</kwd></kwd-group><counts><fig-count count="3"/><table-count count="4"/><equation-count count="0"/><ref-count count="74"/><page-count count="19"/><word-count count="9054"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="S001"><title>Introduction</title><p>Chronic and severe presentations of pain following a spinal cord injury (SCI) are common (<xref rid="CIT0001" ref-type="bibr">1</xref>). Pain often has a large impact on an individual&#8217;s capacity to participate in daily activities, contributing to poorer quality of life and higher rates of depression (<xref rid="CIT0002" ref-type="bibr">2</xref>, <xref rid="CIT0003" ref-type="bibr">3</xref>). Similar to other forms of chronic non-cancer pain, SCI-related pain has broader societal and economic burden associated with reduced participation in work and pain-related hospital admissions (<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0005" ref-type="bibr">5</xref>). Consequently, pain in people with SCI is regularly considered a clinical management priority, and opioids are one medication class often prescribed. The large escalations in the global prescribing and dispensing of opioids and related harms including respiratory depression, potential for addiction, drug-related misuse and hospitalizations; and death have been well-documented among general populations (<xref rid="CIT0006" ref-type="bibr">6</xref>, <xref rid="CIT0007" ref-type="bibr">7</xref>). However, far less is known in specific populations, including people with SCI. This is concerning, as many factors following a SCI can exacerbate opioid-related risks.</p><p>Secondary complications following a SCI are typical, often contributing to reduced respiratory functioning and bowel problems (<xref rid="CIT0008" ref-type="bibr">8</xref>), the first of which can be exacerbated by the mechanistic action of opioids; and the latter being a common side-effect of opioids. Furthermore, many people with SCI are taking multiple other medications (e.g. anticonvulsants, antidepressants) concurrently which increases the potential of drug&#8211;drug interactions (<xref rid="CIT0009" ref-type="bibr">9</xref>). Further risks in people with SCI relate to altered physiological functions affecting how analgesics (including opioids) are absorbed, distributed within the body, metabolized and excreted (<xref rid="CIT0010" ref-type="bibr">10</xref>). SCI-specific pain classifications (i.e. the International Spinal Cord Injury Pain Classification (<xref rid="CIT0011" ref-type="bibr">11</xref>)) have enabled standardization of various types of SCI-specific pain (e.g. neuropathic pain) which are used to guide clinical management options (<xref rid="CIT0011" ref-type="bibr">11</xref>). Current clinical practice guidelines recommend that opioids are considered as a fourth-line option in the management of neuropathic pain, with evidence supporting the prescription of gabapentin and pregabalin ahead of opioids (<xref rid="CIT0012" ref-type="bibr">12</xref>). Despite current evidence-based management guidelines, opioids are frequently prescribed to those with SCI, and compared to the general population, they are more likely to receive prescriptions for high morphine-equivalent doses of long-acting opioids (<xref rid="CIT0013" ref-type="bibr">13</xref>).</p><p>The majority of opioids are prescribed in the community by general practitioners (<xref rid="CIT0014" ref-type="bibr">14</xref>), who are not necessarily familiar with the complexity of SCI, including injury-specific pain and the nuances of its management. There has been some previous research examining opioid prescribing practices in people with SCI, including a recent scoping review on the topic (<xref rid="CIT0015" ref-type="bibr">15</xref>). However, this review considered a limited scope of articles published between 2014 and 2021 and while prevalence of opioid use was reported (identified among 7 of the 16 included articles), it was not the main outcome. Consequently, there remains a clear need for a deeper understanding of historical and current prescribing trends within this population. The aim of this systematic review and meta-analysis is to synthesize evidence relating to the prevalence of opioid use among adults with SCI.</p></sec><sec disp-level="1" id="S002"><title>Review questions</title><p>The current systematic review sought to address the following primary research question: what is the prevalence of prescription opioid use among adults with SCI? In addition, secondary research questions were: (a) what are the associated harms, adverse effects or events related to prescription opioid use for adults with SCI? and (b) what personal characteristics are associated with prescription opioid use?</p></sec><sec sec-type="methods" disp-level="1" id="S003"><title>Methods</title><sec disp-level="2" id="S003-S2001"><title>Study protocol</title><p>This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (<xref rid="CIT0016" ref-type="bibr">16</xref>). The review was prospectively registered in the PROSPERO database (CRD42022350768).</p><p>To assist with reader clarity, the term &#8216;<italic toggle="yes">opioid use&#8217;</italic> will be used throughout this review irrespective of the method in which opioid data was measured. For example, dispensing data reflects medications that are dispensed through pharmacies but may not necessarily be consumed. Similarly, charted medications may reflect either medications prescribed by practitioners at the medical facility or self-reported medications being used by patients. This is distinct from either prescribing data or self-reported use of opioids. However, each of these methods of data capturing reflects a general approach to measuring and understanding opioid use among a group of participants. As such, opioid use will be used throughout, unless otherwise specified.</p></sec><sec disp-level="2" id="S003-S2002"><title>Main outcomes</title><p>The main outcome was prevalence of opioid use among SCI populations. Both point prevalence (opioids used at a specific time, e.g. current opioid use) and period prevalence (opioids used over a specified time, e.g. 12 months) were included (<xref rid="CIT0017" ref-type="bibr">17</xref>). For studies where data was collected directly from participants that captured both period and point prevalence, only point prevalence was used to reduce errors from participant recall.</p><p>To avoid inadvertently overestimating prevalence, studies that captured &#8216;pain medications&#8217; without specifying opioids were excluded on the basis that participants may report non-opioid medications being taken for pain. When prescription opioid prevalence was reported, secondary outcomes were also extracted (if reported). Secondary outcomes were: (1) opioid dose, (2) adverse effects relating to prescription opioids; (3) opioid effectiveness and (4) characteristics associated with prescription opioids. Considered characteristics included but were not limited to personal, health and injury factors.</p></sec><sec disp-level="2" id="S003-S2003"><title>Searches strategy</title><p>A comprehensive search from 1 January 2000 to 7 September 2023 was conducted in five databases: PubMed (MEDLINE), EMBASE, CINAHL, Web of Science and Scopus. The search strategy was designed in conjunction with an experienced librarian, and searches were undertaken by the principal investigator. Language was limited to English, and key terms relating to opioid prescribing, dispensing or use among people with SCI were included. The full search strategy is detailed in Supplement 1.</p></sec><sec disp-level="2" id="S003-S2004"><title>Eligibility criteria</title><p>Empirical quantitative observational studies without intervention (e.g. prospective or retrospective cohort studies, cross-sectional studies) for adults (&#8805;18 years) with SCI and living in community-based settings were considered. With respect to aetiology of the SCI, eligible studies included those which examined people with traumatic SCI only, people with non-traumatic SCI only or studies in which people with both traumatic and non-traumatic aetiology (henceforth referred to as mixed aetiology) were participants. Studies which did not specify whether the aetiology of the SCI was either traumatic or non-traumatic (i.e. <italic toggle="yes">non-specified</italic> aetiology) were also included. Studies based on prescription opioids inclusive of any context (prescribing, dispensing, self-reported use, charted medications) or duration (point or period prevalence) were eligible. Studies were required to be published in English and since the year 2000.</p><p>Studies examining illegal use of prescription opioid analgesics or illegal opioids (e.g. heroin) were excluded. Additional exclusion criteria were: (1) reviews, meta-analyses, case-series and case-reports, (2) prevalence of prescription pain medicines when not explicitly identified as opioids (e.g. <italic toggle="yes">analgesics</italic>, &#8216;<italic toggle="yes">pain medication</italic>&#8217;), (3) inpatient acute or rehabilitation settings, and (4) studies reporting on participants with dual diagnoses of SCI and cancer. Studies involving mixed populations (e.g. other types of injury or disease in addition to SCI) were included if data from participants with SCI was able to be extracted separately.</p></sec><sec disp-level="2" id="S003-S2005"><title>Study selection process</title><p>Search results were imported to Endnote (<xref rid="CIT0018" ref-type="bibr">18</xref>) for duplication detection prior to being uploaded to Rayyan (<xref rid="CIT0019" ref-type="bibr">19</xref>), where blinded title and abstract, and full-text screening were conducted by two independent reviewers (SB and AR). The same two screeners (SB and AR) assessed full-text articles for eligibility criteria, and recorded exclusion reasons. Conflicts during the selection process were resolved by a third investigator (VM).</p></sec><sec disp-level="2" id="S003-S2006"><title>Data extraction</title><p>Data were extracted using an Excel (<xref rid="CIT0020" ref-type="bibr">20</xref>) spreadsheet designed specifically for the study and piloted on a small sample of selected studies in the first instance. Extracted data included: study design, sample size, cohort demographics (e.g. sex, age), injury characteristics, opioid prevalence (incidence and denominator), opioid context (i.e. prescribing, dispensing, self-reported use), prevalence type (i.e. point, period), opioid-related harms, opioid efficacy and factors relating to opioids. Relevant injury and pain characteristics were also extracted, including time since injury, aetiology of SCI (i.e. traumatic only, non-traumatic only, or mixed cohorts), completeness of injury (i.e. complete, incomplete), level of injury (i.e. cervical, non-cervical) and the presence of pain (including pain type if reported).</p></sec><sec disp-level="2" id="S003-S2007"><title>Risk of bias (quality) assessment</title><p>Study-level risk of bias was independently assessed by two reviewers (SB and AR), with any discrepancies resolved by a third reviewer (VM). The risk of bias was determined based on a prevalence-specific tool developed by Hoy and colleagues (<xref rid="CIT0021" ref-type="bibr">21</xref>)<italic toggle="yes">.</italic> The risk of bias tool includes ten questions, with five questions relating to each of (1) external and (2) internal validity. The ten risk of bias questions and the modifications made to contextualize the tool to the current study&#8217;s population are detailed in Supplement 2.</p></sec><sec disp-level="2" id="S003-S2008"><title>Data analysis</title><p>All analyses were conducted in R (<xref rid="CIT0022" ref-type="bibr">22</xref>) using the RStudio environment (<xref rid="CIT0023" ref-type="bibr">23</xref>). Descriptive summaries of study characteristics were completed for: country, data collection method (prescribing or dispensing data, self-reported use or charted medications), prevalence type (point or period), aetiology of SCI (traumatic, non-traumatic or mixed), participant sex and pain presence reported across included studies.</p><sec disp-level="3" id="S003-S2008-S3001"><title>Meta-analyses</title><p>The prevalence of opioid use was pooled from individual studies. We assumed that the true prevalence would differ across populations and accounted for this in the modeling. To do this, prevalence of opioid use was determined as the incidence of opioids (either used, dispensed, charted or prescribed) divided by the number of individuals with SCI in the study. Where studies reported opioid incidence for a subset of participants (e.g. only participants who reported pain), the subset was used as the denominator. This was consistent with choosing the lower risk level as determined by the risk of bias assessment utilized for this review (<xref rid="CIT0021" ref-type="bibr">21</xref>). Studies that included propensity-score matched cohorts (e.g. SCI with neuropathic pain and SCI without neuropathic pain) and reported the prevalence of opioid dispensing separately for each matched cohort were included in the meta-analysis as separate cohorts. As such, the number of populations included in the meta-analysis exceeds the number of studies included in this review.</p><p>To determine the overall prevalence of opioid use among adult populations with SCI, a random-effects meta-analysis was conducted using the <italic toggle="yes">metaprop</italic> function from the <italic toggle="yes">meta</italic> package (<xref rid="CIT0024" ref-type="bibr">24</xref>). A generalized linear mixed model with Logit transformation approach was used (<xref rid="CIT0025" ref-type="bibr">25</xref>). This approach is considered an appropriate method compared to the Freeman-Tukey double arcsine transformation, in the use of single proportion meta-analyses (<xref rid="CIT0026" ref-type="bibr">26</xref>). The Clopper&#8211;Pearson method was implemented to adjust the confidence intervals (CIs) of the overall estimate. Prevalence and 95% CIs were presented using forest plots.</p><p>Between-study heterogeneity was assessed using prediction intervals. In interpreting the results, we based our conclusions on the prediction interval as it accounts for between-study heterogeneity (unlike the 95% CI) and has a more practical interpretation than other measures of heterogeneity (<xref rid="CIT0027" ref-type="bibr">27</xref>). The <italic toggle="yes">I</italic><sup>2</sup> and the variance of (the distribution of) the true effect sizes (<italic toggle="yes">&#964;</italic><sup>2</sup>) are also reported for transparency. Where data could not be pooled, a narrative synthesize was completed.</p></sec><sec disp-level="3" id="S003-S2008-S3002"><title>Sensitivity analyses</title><p>Following the examination of an overall effect size for individual studies, a sensitivity analysis was conducted to determine whether studies assessed as high risk regarding the main outcome (opioid use) had an effect on the pooled prevalence. The same meta-analysis approach described above was carried out for studies after exclusion of those with high risk of bias. The effect of individual studies on the overall pooled prevalence was assessed based on the leave-one-out approach, conducted using the <italic toggle="yes">metainf</italic> function (<xref rid="CIT0028" ref-type="bibr">28</xref>).</p></sec><sec disp-level="3" id="S003-S2008-S3003"><title>Subgroup analyses</title><p>It was assumed that there would be heterogeneity across the included papers and differences in prevalence were explored through subgroup analyses. Subgroup analyses explored the effect of the data collection method (self-reported, charted medication, prescribing or dispensing data) and prevalence type (point or period). These two characteristics were chosen as they were deemed likely to have an impact on the prevalence of opioid use, pending whether the data was self-reported or derived from pharmaceutical datasets; and whether opioid use was considered over a period or at a single point in time. A subgroup analysis was also conducted for studies that reported a prevalence of opioid use based on duration of opioid action (short- and long-acting). A final subgroup analysis was conducted based on the time since injury of included studies (1 year; 2&#8211;10 years; 10&#8211;15 years; over 15 years), given pain and subsequently opioid use is likely to fluctuate over time following injury. All sensitivity and subgroup analyses were conducted using the same random-effects meta-analysis approach described above.</p></sec></sec></sec><sec sec-type="results" disp-level="1" id="S004"><title>Results</title><sec disp-level="2" id="S004-S2001"><title>Search results</title><p>There were 4969 citations identified from the search process, of which 40 articles met eligibility criteria. Two articles were found to report results from the same data source and with the same sample of people with SCI (<xref rid="CIT0029" ref-type="bibr">29</xref>, <xref rid="CIT0030" ref-type="bibr">30</xref>). Neither of these studies offered additional information relating to the secondary aims of this review and consequently were excluded to avoid duplication in the meta-analysis. As such, 38 articles were included in this review. The PRISMA study selection flow diagram is presented in <xref rid="F0001" ref-type="fig">Figure 1</xref>.
<fig position="float" id="F0001" orientation="portrait"><label>Figure 1</label><caption><p>Preferred reporting items for systematic review and meta-analyses (PRISMA) flow diagram.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="YSCM_A_2319384_F0001_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="YSCM_A_2319384_F0001_PB.jpg"/></alternatives></fig></p></sec><sec disp-level="2" id="S004-S2002"><title>Study characteristics</title><p>A description of cohorts, the opioid data source, prevalence type, injury index period, and observation period for the 38 studies included in the review are provided in <xref rid="T0001" ref-type="table">Table 1</xref> (<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0013" ref-type="bibr">13</xref>, <xref rid="CIT0031" ref-type="bibr">31&#8211;66</xref>). The majority of studies were based in the USA (20/38, 53%) and Canada (7/38, 18%) (<xref rid="CIT0042" ref-type="bibr">42&#8211;46</xref>, <xref rid="CIT0058" ref-type="bibr">58</xref>, <xref rid="CIT0059" ref-type="bibr">59</xref>), with two studies from each Sweden (2/38, 5%) (<xref rid="CIT0056" ref-type="bibr">56</xref>, <xref rid="CIT0057" ref-type="bibr">57</xref>) and Denmark (2/38, 5%) (<xref rid="CIT0041" ref-type="bibr">41</xref>, <xref rid="CIT0055" ref-type="bibr">55</xref>). The remaining studies were each conducted in a single country (e.g. Australia (<xref rid="CIT0032" ref-type="bibr">32</xref>), Iran (<xref rid="CIT0035" ref-type="bibr">35</xref>)).
<table-wrap position="float" id="T0001" orientation="portrait"><label>Table 1</label><caption><p>Cohort description, opioid data source, injury index period, prevalence type, observation period and sample size (<italic toggle="yes">n</italic>&#8201;=&#8201;38).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="1" rowspan="1">Country</th><th align="center" colspan="1" rowspan="1">Author</th><th align="center" colspan="1" rowspan="1">Year</th><th align="center" colspan="1" rowspan="1">SCI cause</th><th align="center" colspan="1" rowspan="1">Cohort description</th><th align="center" colspan="1" rowspan="1">Opioid data source</th><th align="center" colspan="1" rowspan="1">Injury index period</th><th align="center" colspan="1" rowspan="1">Prev. type</th><th align="center" colspan="1" rowspan="1">Prev. period</th><th align="center" colspan="1" rowspan="1">Observation / recruitment period</th><th align="center" colspan="1" rowspan="1">Sample size</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Iran</td><td align="left" colspan="1" rowspan="1">Behnaz</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Males, aged &#8805;18, with chronic SCI and erectile dysfunction.</td><td align="left" colspan="1" rowspan="1">Hospital medical records</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">NR</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Jan 2013&#8211;Mar 2015</td><td align="left" colspan="1" rowspan="1">319</td></tr><tr><td align="left" colspan="1" rowspan="1">Ireland</td><td align="left" colspan="1" rowspan="1">Burke</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">Aged &#8805;18 and a member of Spinal Injuries Ireland (SII).</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">6-m</td><td align="left" colspan="1" rowspan="1">Not reported</td><td align="left" colspan="1" rowspan="1">643</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Carbone</td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">Male veterans with traumatic SCI for &#8805;2yrs. Identified by Veteran Affairs Spinal cord dysfunction registry.</td><td align="left" colspan="1" rowspan="1">VA pharmacy benefits management group prescription database</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">5-yr</td><td align="left" colspan="1" rowspan="1">FY2002 to FY2007</td><td align="left" colspan="1" rowspan="1">7447</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Cardenas</td><td align="left" colspan="1" rowspan="1">2006</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">Traumatic SCI, aged &#8805;18, with chronic pain (pain within the previous 3-months before responding to the survey).</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Point<xref rid="TF5" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not reported</td><td align="left" colspan="1" rowspan="1">117</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Carlozzi</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Aged &#8805;18 with a medically documented SCI, fluent in English and able to consent.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Point</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not reported</td><td align="left" colspan="1" rowspan="1">173</td></tr><tr><td align="left" colspan="1" rowspan="1">Europe</td><td align="left" colspan="1" rowspan="1">Cragg</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">Adults able to consent and participate in the first study assessment within 6 weeks of the SCI.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Point</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">225</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">DiPiro</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Individuals with a newly diagnosed SCI in 2013&#8211;14, living in South Carolina and alive during the 2&#8211;3 year follow-up period.</td><td align="left" colspan="1" rowspan="1">South Carolina Reporting &amp; Identification Prescription Tracking System (SCRIPTS)</td><td align="left" colspan="1" rowspan="1">2013&#8211;2014</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">2-yr</td><td align="left" colspan="1" rowspan="1">2015&#8211;2016<xref rid="TF6" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" colspan="1" rowspan="1">503</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Durga</td><td align="left" colspan="1" rowspan="1">2011</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Convenience sample of male Veterans with chronic SCI, presenting for annual evaluation from July 2006 to Apr 2007.</td><td align="left" colspan="1" rowspan="1">Milwaukee Veterans Affairs Medical Centre</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Period<xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" colspan="1" rowspan="1">NR</td><td align="left" colspan="1" rowspan="1">July 2006 to April 2007</td><td align="left" colspan="1" rowspan="1">60</td></tr><tr><td align="left" colspan="1" rowspan="1">DEN</td><td align="left" colspan="1" rowspan="1">Finnerup</td><td align="left" colspan="1" rowspan="1">2001</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">Outpatients of the Viborg rehabilitation center for SCI. Minimal cohort details provided.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Point</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not reported</td><td align="left" colspan="1" rowspan="1">330</td></tr><tr><td align="left" colspan="1" rowspan="1">UK</td><td align="left" colspan="1" rowspan="1">Gore</td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Aged &#8805;18 with SCI on or after 1 July 2004 who initiated pregabalin at least 9 months after their SCI diagnosis, with 9-month pre- and 9-month post-index data.</td><td align="left" colspan="1" rowspan="1">The Health Improvement Network (anonymized general practice records)</td><td align="left" colspan="1" rowspan="1">Diagnosed on/after 1 July 2004</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">9-m</td><td align="left" colspan="1" rowspan="1">Not reported</td><td align="left" colspan="1" rowspan="1">72</td></tr><tr><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">Guan</td><td align="left" colspan="1" rowspan="1">2021a</td><td align="left" colspan="1" rowspan="1">Non-trauma</td><td align="left" colspan="1" rowspan="1">Non-traumatic SCI, aged &gt;18, eligible for provincial drug coverage program.</td><td align="left" colspan="1" rowspan="1">Ontario Drug Benefit Database</td><td align="left" colspan="1" rowspan="1">1 Apr 2004 to 31 Mar 2015</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">2004&#8211;2015</td><td align="left" colspan="1" rowspan="1">3468</td></tr><tr><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">Guan</td><td align="left" colspan="1" rowspan="1">2021b</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">Individuals eligible for the provincial drug coverage, who had a traumatic SCI during the index period.</td><td align="left" colspan="1" rowspan="1">Ontario Drug Benefit Database</td><td align="left" colspan="1" rowspan="1">1 Apr 2004 to 31 Mar 2015</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">2004&#8211;2015</td><td align="left" colspan="1" rowspan="1">934</td></tr><tr><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">Guilcher</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">Aged &#8805;66 at the time of hospitalization for traumatic SCI.</td><td align="left" colspan="1" rowspan="1">Ontario Drug Benefit Database</td><td align="left" colspan="1" rowspan="1">1 Apr 2004 to 31 Ma 2014</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">2004&#8211;2014</td><td align="left" colspan="1" rowspan="1">418</td></tr><tr><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">Guilcher</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">Traumatic SCI acquired during the index period.</td><td align="left" colspan="1" rowspan="1">Narcotics Monitoring System Database</td><td align="left" colspan="1" rowspan="1">1 Apr 2004 to 31 Mar 2015</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">1 Apr 2016 to 31 Mar 2017</td><td align="left" colspan="1" rowspan="1">1842</td></tr><tr><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">Gupta</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">Aged &#8805;18, community dwelling, living in Canada and prescribed &#8805;1 medication at the time of the survey.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">May to Oct 2018</td><td align="left" colspan="1" rowspan="1">160</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Hand</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Aged: 18&#8211;64 years. Propensity-score matched opioid users with SCI and opioid users without SCI. Required to have &#8805;18 months of continuous insurance coverage from the date of the first opioid claim.</td><td align="left" colspan="1" rowspan="1">MarketScan Commercial Claims and Encounters Database</td><td align="left" colspan="1" rowspan="1">1 Jan to 31 Dec 2012</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">2012&#8211;2013</td><td align="left" colspan="1" rowspan="1">1454</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Hatch</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">Veterans, aged &#8805;18 with SCI/dysfunction, using Medicare or Veteran Affairs pharmacy benefits.</td><td align="left" colspan="1" rowspan="1">VA Managerial Cost Accounting National Data Extract Pharmacy Databases</td><td align="left" colspan="1" rowspan="1">Injuries prior to 2011</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">2011</td><td align="left" colspan="1" rowspan="1">13,442</td></tr><tr><td align="left" colspan="1" rowspan="1">NL</td><td align="left" colspan="1" rowspan="1">Heutink</td><td align="left" colspan="1" rowspan="1">2011</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">Aged &#8805;18, chronic pain, living in the community &amp; attended the Rehabilitation Centre &#8216;De Hoogstraat&#8217; from 1990 to 2005.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Point<xref rid="TF5" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1990&#8211;2005</td><td align="left" colspan="1" rowspan="1">215</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Hwang</td><td align="left" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Adults with pediatric onset SCI who received rehabilitation services at one of the SCI specialty programs in Chicago, Philadelphia or Northern California.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Period<xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" colspan="1" rowspan="1">NR</td><td align="left" colspan="1" rowspan="1">Jan 2011</td><td align="left" colspan="1" rowspan="1">159</td></tr><tr><td align="left" colspan="1" rowspan="1">AUS</td><td align="left" colspan="1" rowspan="1">Karran</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">Aged &#8805;18, with SCI, who experience persistent pain.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">6-m</td><td align="left" colspan="1" rowspan="1">Not reported</td><td align="left" colspan="1" rowspan="1">43</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Kokorelis</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">Males aged &#8805;21, who were evaluated over a 10-year period at a SCI-specialized centre for trauma-induced SCI</td><td align="left" colspan="1" rowspan="1">Medical records from a specialized SCI center.</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Point</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">June 2005 &#8211; June 2015</td><td align="left" colspan="1" rowspan="1">279</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Kratz</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Aged &gt;18, at least &gt;1-year post-SCI, with chronic pain (defined as &gt;4/10 average pain in the past month).</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Point</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">June 2014 to Jan 2016</td><td align="left" colspan="1" rowspan="1">120</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Mann</td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Aged &gt;18, with chronic SCI (&#8805;1 year) and diagnosed with NeP managed at their physician&#8217;s practice for &#8805;6 months.</td><td align="left" colspan="1" rowspan="1">Medical records from 14 community-based physician practices</td><td align="left" colspan="1" rowspan="1">Injuries prior to Sept 2010</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">6-m</td><td align="left" colspan="1" rowspan="1">Sept 2011 &#8211;June 2012</td><td align="left" colspan="1" rowspan="1">103</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Margolis</td><td align="left" colspan="1" rowspan="1">2014a</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">Aged &#8805;18 and <italic toggle="yes">commercially insured.</italic> All individuals with SCI, propensity-score matched with and without NeP.</td><td align="left" colspan="1" rowspan="1">MarketScan Commercial Database</td><td align="left" colspan="1" rowspan="1">1 Jan 2006 to 30 June 2011</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">1 Jan 2005&#8211;30 June 2012</td><td align="left" colspan="1" rowspan="1">7048<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Margolis</td><td align="left" colspan="1" rowspan="1">2014b</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">Aged &#8805;18 at injury, with SCI and propensity-score matched with and without NeP. Required to have &#8805;6 months of continuous <italic toggle="yes">Medicaid eligibility</italic> prior to injury.</td><td align="left" colspan="1" rowspan="1">MarketScan Multi-state Medicaid Database</td><td align="left" colspan="1" rowspan="1">1 Jan 2006 to 30 June 2011</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">1 Jan 2005&#8211;30 June 2012</td><td align="left" colspan="1" rowspan="1">1092<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">McCasland</td><td align="left" colspan="1" rowspan="1">2006</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">Aged &#8805;20; convenience sample of traumatic SCD registry</td><td align="left" colspan="1" rowspan="1">Survey data, validated with medical records</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">NR</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Jan 2000&#8211;Dec 2002</td><td align="left" colspan="1" rowspan="1">63</td></tr><tr><td align="left" colspan="1" rowspan="1">DEN</td><td align="left" colspan="1" rowspan="1">Nielsen</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Members of a Danish SCI organization.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Point</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">24 Sept-1 Dec 2015</td><td align="left" colspan="1" rowspan="1">130</td></tr><tr><td align="left" colspan="1" rowspan="1">SWE</td><td align="left" colspan="1" rowspan="1">Norrbrink Budh</td><td align="left" colspan="1" rowspan="1">2003</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">People with SCI attending Spinalis SCI unit for a yearly assessment were asked to fill in pain questionnaires.</td><td align="left" colspan="1" rowspan="1">Data from annual medical assessment.</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">NR</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1999</td><td align="left" colspan="1" rowspan="1">130</td></tr><tr><td align="left" colspan="1" rowspan="1">SWE</td><td align="left" colspan="1" rowspan="1">Norrbrink Budh</td><td align="left" colspan="1" rowspan="1">2005</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">People with SCI attending Spinalis SCI unit who completed the previous survey from Norrbrink <italic toggle="yes">et al.</italic>, 2003</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Point</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">2002</td><td align="left" colspan="1" rowspan="1">90</td></tr><tr><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">Patel</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Adults with a documented SCI, attending a primary care clinic in Ontario.</td><td align="left" colspan="1" rowspan="1">Medical records from a primary care clinic</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Point</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Aug 2012 &#8211; Mar 2013</td><td align="left" colspan="1" rowspan="1">19</td></tr><tr><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">Rouleau</td><td align="left" colspan="1" rowspan="1">2011</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">All SCI patients through Interval Rehabilitation Centre in Quebec, Canada.</td><td align="left" colspan="1" rowspan="1">Medical records from a Rehabilitation Centre</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">NR</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Not reported</td><td align="left" colspan="1" rowspan="1">151</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Tsai <italic toggle="yes">et al.</italic></td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">Aged &#8805;18, with non-NeP,&#8201;&#8805;&#8201;1-year post-injury and enrolled in one of six participating SCI centers.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">Mar 2017&#8211;July 2019</td><td align="left" colspan="1" rowspan="1">190</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Turner</td><td align="left" colspan="1" rowspan="1">2001</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Aged &#8805;18, with SCI.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Period<xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" colspan="1" rowspan="1">NR</td><td align="left" colspan="1" rowspan="1">Feb 1997&#8211;July 1998</td><td align="left" colspan="1" rowspan="1">384</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Ullrich</td><td align="left" colspan="1" rowspan="1">2014</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">Veterans with SCI diagnosed with and without depression. Reported as 2 distinct samples.</td><td align="left" colspan="1" rowspan="1">Veterans Health Administration National Registry for Depression</td><td align="left" colspan="1" rowspan="1">FY1997 to FY2007</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">2007</td><td align="left" colspan="1" rowspan="1">2796</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Warms</td><td align="left" colspan="1" rowspan="1">2002</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Aged &#8805;18, with SCI and pain. Reported as two samples: Sample 1 is reported in Turner <italic toggle="yes">et al</italic>., 2001. Only Sample 2 included in this review.</td><td align="left" colspan="1" rowspan="1">Survey data (only Sample 2, as Sample 1 is accounted for already).</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Point<xref rid="TF5" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Aug 1998 &#8211; June 2000</td><td align="left" colspan="1" rowspan="1">163</td></tr><tr><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">Wen</td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">Patients who sustained a SCI in the 2008 Sichuan earthquake.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">May 2008</td><td align="left" colspan="1" rowspan="1">NR</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Oct 2012</td><td align="left" colspan="1" rowspan="1">26</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Widerstrom-Noga</td><td align="left" colspan="1" rowspan="1">2003</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">Aged &#8805;18 years, chronic SCI (&#8805;18 mths), who reported chronic pain/nonpainful sensations in the preceding study.</td><td align="left" colspan="1" rowspan="1">Survey data</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">18-m</td><td align="left" colspan="1" rowspan="1">Not reported</td><td align="left" colspan="1" rowspan="1">120</td></tr><tr><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">Wilkinson</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">Aged &#8805;18 years, traumatic SCI, with &#8805;12 months of pre-injury and &#8805;15-months of post-injury data.</td><td align="left" colspan="1" rowspan="1">MarketScan Research Database</td><td align="left" colspan="1" rowspan="1">2009&#8211;2019</td><td align="left" colspan="1" rowspan="1">Period</td><td align="left" colspan="1" rowspan="1">12-m</td><td align="left" colspan="1" rowspan="1">2009&#8211;2019</td><td align="left" colspan="1" rowspan="1">7187</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>Abbreviations: FY&#8201;=&#8201;financial year; N/A&#8201;=&#8201;not applicable; NeP&#8201;=&#8201;neuropathic pain; NR&#8201;=&#8201;not reported; SCI&#8201;=&#8201;spinal cord injury; VA&#8201;=&#8201;Veterans Affairs.</p></fn><fn id="TF2"><label><sup>a</sup></label><p>SCI onset not specified (traumatic or non-traumatic), assumed to be a mixed cohort.</p></fn><fn id="TF3"><label><sup>b</sup></label><p>Reported in article as two distinct sub-populations.</p></fn><fn id="TF4"><label><sup>c</sup></label><p>Period of prevalence not specified, identified as &#8216;routinely&#8217; or &#8216;regularly&#8217; taken medications.</p></fn><fn id="TF5"><label><sup>d</sup></label><p>Period (past medications) and point prevalence both reported but only point prevalence extracted and used for this review.</p></fn><fn id="TF6"><label><sup>e</sup></label><p>Observation period inferred from methods section details.</p></fn></table-wrap-foot></table-wrap></p><p>Self-reported use of opioids was the most common data collection method, used in 47% of studies (18/38), followed by dispensed pharmaceutical datasets (11/38, 29%) and medications extracted from medical charts (7/38, 18%). Prescription datasets were only used in two studies (2/39, 5%). Fifty-eight percent (22/38) of studies utilized period prevalence. The most common period used to capture opioid use was 12-months (12/22, 55%), however, periods ranged from 6-months to 5-years (<xref rid="T0001" ref-type="table">Table 1</xref>). Three studies did not provide enough details to identify the period for which prevalence of opioid use was captured (<xref rid="CIT0040" ref-type="bibr">40</xref>, <xref rid="CIT0050" ref-type="bibr">50</xref>, <xref rid="CIT0061" ref-type="bibr">61</xref>). Point prevalence was used to capture opioid use among 11 studies, while 5 studies did not provide sufficient detail to classify whether prevalence type was period or point (<xref rid="CIT0035" ref-type="bibr">35</xref>, <xref rid="CIT0054" ref-type="bibr">54</xref>, <xref rid="CIT0056" ref-type="bibr">56</xref>, <xref rid="CIT0059" ref-type="bibr">59</xref>, <xref rid="CIT0064" ref-type="bibr">64</xref>).</p><p>Many studies did not specify the aetiology of the SCI of participants (14/38, 37%), and for these studies the aetiology was assumed to include a mix of both traumatic and non-traumatic SCI (i.e. mixed aetiology). The remaining studies specified aetiology for participants, including 13 (34%) with mixed aetiology, 10 (26%) that were exclusively of traumatic aetiology and one study that was exclusively non-traumatic SCI. Four studies (11%) included males only populations (<xref rid="CIT0034" ref-type="bibr">34</xref>, <xref rid="CIT0035" ref-type="bibr">35</xref>, <xref rid="CIT0040" ref-type="bibr">40</xref>, <xref rid="CIT0051" ref-type="bibr">51</xref>). The presence of pain (inclusive of all types) was reported for nearly two-thirds of studies (22/38, 58%, <xref rid="T0002" ref-type="table">Table 2</xref>) and a criterion for the individual participant eligibility in 29% (11/38) of studies (<xref rid="T0001" ref-type="table">Table 1</xref>).
<table-wrap position="float" id="T0002" orientation="portrait"><label>Table 2</label><caption><p>Included studies for meta-analysis (41 cohorts reported from 38 articles).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/></colgroup><thead valign="bottom"><tr><th rowspan="2" align="left" colspan="1">First author</th><th rowspan="2" align="center" colspan="1">Year</th><th rowspan="2" align="center" colspan="1">Country</th><th rowspan="2" align="center" colspan="1">Design</th><th rowspan="2" align="center" colspan="1">Cohort type</th><th rowspan="2" align="center" colspan="1">SCI cohort<xref rid="TF10" ref-type="table-fn"><sup>b</sup></xref> (N)</th><th rowspan="2" align="center" colspan="1">Male (N)</th><th rowspan="2" align="center" colspan="1">Mean age (yrs)</th><th colspan="4" align="center" rowspan="1">Injury characteristics</th><th rowspan="2" align="center" colspan="1">Opioid type</th><th rowspan="2" align="center" colspan="1">Opioid incidence (N)</th><th rowspan="2" align="center" colspan="1">Denominator (N)</th><th rowspan="2" align="center" colspan="1">Prevalence</th><th colspan="4" align="center" rowspan="1">Pain</th></tr><tr><th align="center" colspan="1" rowspan="1">Cervical (N)</th><th align="center" colspan="1" rowspan="1">Complete (N)</th><th align="center" colspan="1" rowspan="1">Mean TSI (yrs)</th><th align="center" colspan="1" rowspan="1">Trauma (N)</th><th align="center" colspan="1" rowspan="1">All types</th><th align="center" colspan="1" rowspan="1">NeP</th><th align="center" colspan="1" rowspan="1">NI</th><th align="center" colspan="1" rowspan="1">MS</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><bold><sc>Use</sc></bold></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Finnerup</td><td align="left" colspan="1" rowspan="1">2001</td><td align="left" colspan="1" rowspan="1">DEN</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">330</td><td align="left" colspan="1" rowspan="1">230</td><td align="left" colspan="1" rowspan="1">43<xref rid="TF11" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" colspan="1" rowspan="1">113</td><td align="left" colspan="1" rowspan="1">159<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">9<xref rid="TF11" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" colspan="1" rowspan="1">258</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">36<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">255</td><td align="char" char="." colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">255</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Turner</td><td align="left" colspan="1" rowspan="1">2001</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">384</td><td align="left" colspan="1" rowspan="1">283<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">43</td><td align="left" colspan="1" rowspan="1">196<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">143<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">308<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">186<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">384</td><td align="char" char="." colspan="1" rowspan="1">48.5</td><td align="left" colspan="1" rowspan="1">304</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Warms</td><td align="left" colspan="1" rowspan="1">2002</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">163</td><td align="left" colspan="1" rowspan="1">114<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">42</td><td align="left" colspan="1" rowspan="1">85</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">4<xref rid="TF11" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" colspan="1" rowspan="1">142<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">163</td><td align="char" char="." colspan="1" rowspan="1">28.8</td><td align="left" colspan="1" rowspan="1">163</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Widerstr&#246;m-Noga</td><td align="left" colspan="1" rowspan="1">2003</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">120</td><td align="left" colspan="1" rowspan="1">94</td><td align="left" colspan="1" rowspan="1">41</td><td align="left" colspan="1" rowspan="1">62</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">120</td><td align="char" char="." colspan="1" rowspan="1">22.5</td><td align="left" colspan="1" rowspan="1">120</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Norrbrink Budh</td><td align="left" colspan="1" rowspan="1">2005</td><td align="left" colspan="1" rowspan="1">SWE</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">44</td><td align="left" colspan="1" rowspan="1">53</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">70</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">31</td><td align="left" colspan="1" rowspan="1">90</td><td align="char" char="." colspan="1" rowspan="1">34.4</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">43</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Cardenas</td><td align="left" colspan="1" rowspan="1">2006</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">117</td><td align="left" colspan="1" rowspan="1">85</td><td align="left" colspan="1" rowspan="1">49</td><td align="left" colspan="1" rowspan="1">56<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">117</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">117</td><td align="char" char="." colspan="1" rowspan="1">21.4</td><td align="left" colspan="1" rowspan="1">117</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">McCasland</td><td align="left" colspan="1" rowspan="1">2006</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">CR/CSS</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">63</td><td align="left" colspan="1" rowspan="1">61</td><td align="left" colspan="1" rowspan="1">58</td><td align="left" colspan="1" rowspan="1">32<xref rid="TF13" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-<xref rid="TF16" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" colspan="1" rowspan="1">63</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">63</td><td align="char" char="." colspan="1" rowspan="1">6.3</td><td align="left" colspan="1" rowspan="1">44</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Heutink</td><td align="left" colspan="1" rowspan="1">2011</td><td align="left" colspan="1" rowspan="1">NL</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">215</td><td align="left" colspan="1" rowspan="1">133</td><td align="left" colspan="1" rowspan="1">51</td><td align="left" colspan="1" rowspan="1">80<xref rid="TF13" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" colspan="1" rowspan="1">92</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">138</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">13<xref rid="TF15" ref-type="table-fn"><sup>g</sup></xref></td><td align="left" colspan="1" rowspan="1">207</td><td align="char" char="." colspan="1" rowspan="1">6.3</td><td align="left" colspan="1" rowspan="1">215</td><td align="left" colspan="1" rowspan="1">149</td><td align="left" colspan="1" rowspan="1">65</td><td align="left" colspan="1" rowspan="1">131</td></tr><tr><td align="left" colspan="1" rowspan="1">Wen</td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">PC</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">51</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">22</td><td align="char" char="." colspan="1" rowspan="1">9.1</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">6</td></tr><tr><td align="left" colspan="1" rowspan="1">Hwang</td><td align="left" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">159</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1">35</td><td align="left" colspan="1" rowspan="1">81</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">159</td><td align="char" char="." colspan="1" rowspan="1">14.5</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Cragg</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Europe</td><td align="left" colspan="1" rowspan="1">PC</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">225</td><td align="left" colspan="1" rowspan="1">180</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">120<xref rid="TF13" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" colspan="1" rowspan="1">82</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">216<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">63</td><td align="left" colspan="1" rowspan="1">225</td><td align="char" char="." colspan="1" rowspan="1">28.0</td><td align="left" colspan="1" rowspan="1">161</td><td align="left" colspan="1" rowspan="1">63</td><td align="left" colspan="1" rowspan="1">96</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Nielsen</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">DEN</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">130</td><td align="left" colspan="1" rowspan="1">94</td><td align="left" colspan="1" rowspan="1">56</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">31</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">41</td><td align="char" char="." colspan="1" rowspan="1">22.5</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Kratz</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">120</td><td align="left" colspan="1" rowspan="1">88</td><td align="left" colspan="1" rowspan="1">47</td><td align="left" colspan="1" rowspan="1">46<xref rid="TF13" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" colspan="1" rowspan="1">65</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">106</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">49</td><td align="left" colspan="1" rowspan="1">120</td><td align="char" char="." colspan="1" rowspan="1">40.8</td><td align="left" colspan="1" rowspan="1">120</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Burke</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">IRE</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">643</td><td align="left" colspan="1" rowspan="1">447</td><td align="left" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">218</td><td align="left" colspan="1" rowspan="1">172</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">456</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">123</td><td align="left" colspan="1" rowspan="1">458</td><td align="char" char="." colspan="1" rowspan="1">26.9</td><td align="left" colspan="1" rowspan="1">458</td><td align="left" colspan="1" rowspan="1">236</td><td align="left" colspan="1" rowspan="1">206</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Gupta</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">160</td><td align="left" colspan="1" rowspan="1">71<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">47</td><td align="left" colspan="1" rowspan="1">53<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">93<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">85</td><td align="left" colspan="1" rowspan="1">160</td><td align="char" char="." colspan="1" rowspan="1">53.1</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Carlozzi</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">173</td><td align="left" colspan="1" rowspan="1">110</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">76<xref rid="TF13" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">173</td><td align="char" char="." colspan="1" rowspan="1">30.1</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Tsai</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">190</td><td align="left" colspan="1" rowspan="1">144</td><td align="left" colspan="1" rowspan="1">51</td><td align="left" colspan="1" rowspan="1">87</td><td align="left" colspan="1" rowspan="1">82</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">190</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">84</td><td align="left" colspan="1" rowspan="1">190</td><td align="char" char="." colspan="1" rowspan="1">44.2</td><td align="left" colspan="1" rowspan="1">190</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Karran</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">AUS</td><td align="left" colspan="1" rowspan="1">CSS</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">43</td><td align="left" colspan="1" rowspan="1">31</td><td align="left" colspan="1" rowspan="1">49</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">31</td><td align="left" colspan="1" rowspan="1">SR</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">43</td><td align="char" char="." colspan="1" rowspan="1">58.1</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold><sc>Charted</sc></bold></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Norrbrink Budh</td><td align="left" colspan="1" rowspan="1">2003</td><td align="left" colspan="1" rowspan="1">SWE</td><td align="left" colspan="1" rowspan="1">OBS/CS</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">130</td><td align="left" colspan="1" rowspan="1">65</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">CR</td><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">130</td><td align="char" char="." colspan="1" rowspan="1">27.7</td><td align="left" colspan="1" rowspan="1">130</td><td align="left" colspan="1" rowspan="1">62</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Mann</td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">OBS/CS</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">103</td><td align="left" colspan="1" rowspan="1">72</td><td align="left" colspan="1" rowspan="1">49</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-<xref rid="TF16" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">CR</td><td align="left" colspan="1" rowspan="1">35<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">103</td><td align="char" char="." colspan="1" rowspan="1">34.0<xref rid="TF14" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" colspan="1" rowspan="1">103</td><td align="left" colspan="1" rowspan="1">103</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Durga</td><td align="left" colspan="1" rowspan="1">2011</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">OBS/CS</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1">31</td><td align="left" colspan="1" rowspan="1">24</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">CR</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">60</td><td align="char" char="." colspan="1" rowspan="1">30.0</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Rouleau</td><td align="left" colspan="1" rowspan="1">2011</td><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">OBS/CS</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">151</td><td align="left" colspan="1" rowspan="1">97</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">67<xref rid="TF13" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">82</td><td align="left" colspan="1" rowspan="1">CR</td><td align="left" colspan="1" rowspan="1">87</td><td align="left" colspan="1" rowspan="1">151</td><td align="char" char="." colspan="1" rowspan="1">57.6</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Behnaz</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Iran</td><td align="left" colspan="1" rowspan="1">OBS/CS</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">319</td><td align="left" colspan="1" rowspan="1">319</td><td align="left" colspan="1" rowspan="1">47</td><td align="left" colspan="1" rowspan="1">43</td><td align="left" colspan="1" rowspan="1">169</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">CR</td><td align="left" colspan="1" rowspan="1">37</td><td align="left" colspan="1" rowspan="1">319</td><td align="char" char="." colspan="1" rowspan="1">11.6</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Patel</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">CRV</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">14<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">47</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">CR</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">19</td><td align="char" char="." colspan="1" rowspan="1">31.6</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Kokorelis</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">279</td><td align="left" colspan="1" rowspan="1">279</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">165<xref rid="TF13" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" colspan="1" rowspan="1">142</td><td align="left" colspan="1" rowspan="1">-<xref rid="TF16" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" colspan="1" rowspan="1">279</td><td align="left" colspan="1" rowspan="1">CR</td><td align="left" colspan="1" rowspan="1">91</td><td align="left" colspan="1" rowspan="1">279</td><td align="char" char="." colspan="1" rowspan="1">32.6</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold><sc>Prescribing</sc></bold></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Carbone</td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">7447</td><td align="left" colspan="1" rowspan="1">7447</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">2138<xref rid="TF13" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" colspan="1" rowspan="1">2724</td><td align="left" colspan="1" rowspan="1">-<xref rid="TF16" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" colspan="1" rowspan="1">7447</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">5106</td><td align="left" colspan="1" rowspan="1">7447</td><td align="char" char="." colspan="1" rowspan="1">68.6</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Gore</td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">UK</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">72</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">PD</td><td align="left" colspan="1" rowspan="1">44</td><td align="left" colspan="1" rowspan="1">72</td><td align="char" char="." colspan="1" rowspan="1">61.1</td><td align="left" colspan="1" rowspan="1">72</td><td align="left" colspan="1" rowspan="1">72</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold><sc>Dispensing</sc></bold></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Margolis</td><td align="left" colspan="1" rowspan="1">2014a</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">3524</td><td align="left" colspan="1" rowspan="1">1916</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">569<sup>d,e</sup></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1343<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">2764<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">3524</td><td align="char" char="." colspan="1" rowspan="1">78.4<xref rid="TF14" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" colspan="1" rowspan="1">3524</td><td align="left" colspan="1" rowspan="1">3524</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1887<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Margolis</td><td align="left" colspan="1" rowspan="1">2014a</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">3524</td><td align="left" colspan="1" rowspan="1">1950</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">614<sup>d,e</sup></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1118<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">1762<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">3524</td><td align="char" char="." colspan="1" rowspan="1">50.0<xref rid="TF14" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" colspan="1" rowspan="1">1826<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1826<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Margolis</td><td align="left" colspan="1" rowspan="1">2014b</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">546</td><td align="left" colspan="1" rowspan="1">240</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">111<sup>e,d</sup></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">166<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">474<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">546</td><td align="char" char="." colspan="1" rowspan="1">86.8<xref rid="TF14" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" colspan="1" rowspan="1">546</td><td align="left" colspan="1" rowspan="1">546</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">272<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Margolis</td><td align="left" colspan="1" rowspan="1">2014b</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">546</td><td align="left" colspan="1" rowspan="1">247</td><td align="left" colspan="1" rowspan="1">42</td><td align="left" colspan="1" rowspan="1">130<xref rid="TF13" ref-type="table-fn"><sup>e</sup></xref><sup>,</sup><xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">122<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">338<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">546</td><td align="char" char="." colspan="1" rowspan="1">61.9<xref rid="TF14" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" colspan="1" rowspan="1">273<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">273<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Ullrich</td><td align="left" colspan="1" rowspan="1">2014</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">2615</td><td align="left" colspan="1" rowspan="1">2482<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">-<xref rid="TF16" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" colspan="1" rowspan="1">1123<sup>e,d</sup></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">1164<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">2615</td><td align="char" char="." colspan="1" rowspan="1">44.5</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Ullrich</td><td align="left" colspan="1" rowspan="1">2014</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">181</td><td align="left" colspan="1" rowspan="1">179<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">-<xref rid="TF16" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" colspan="1" rowspan="1">80<sup>e,d</sup></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">45<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">181</td><td align="char" char="." colspan="1" rowspan="1">25.1</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Guilcher</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">418</td><td align="left" colspan="1" rowspan="1">265</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1">321</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">418</td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">332<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">418</td><td align="char" char="." colspan="1" rowspan="1">79</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Hand</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">1454</td><td align="left" colspan="1" rowspan="1">720</td><td align="left" colspan="1" rowspan="1">46</td><td align="left" colspan="1" rowspan="1">364</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">1190<xref rid="TF12" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" colspan="1" rowspan="1">1454</td><td align="char" char="." colspan="1" rowspan="1">81.8<xref rid="TF14" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Hatch</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Mixed</td><td align="left" colspan="1" rowspan="1">13442</td><td align="left" colspan="1" rowspan="1">12948</td><td align="left" colspan="1" rowspan="1">-<xref rid="TF16" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" colspan="1" rowspan="1">5526<xref rid="TF13" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-<xref rid="TF16" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" colspan="1" rowspan="1">4176<xref rid="TF17" ref-type="table-fn"><sup>i</sup></xref></td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">5890</td><td align="left" colspan="1" rowspan="1">12161<xref rid="TF18" ref-type="table-fn"><sup>j</sup></xref></td><td align="char" char="." colspan="1" rowspan="1">48.4</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">DiPiro</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Mixed<xref rid="TF9" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" colspan="1" rowspan="1">503</td><td align="left" colspan="1" rowspan="1">357</td><td align="left" colspan="1" rowspan="1">-<xref rid="TF16" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" colspan="1" rowspan="1">303</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">269</td><td align="left" colspan="1" rowspan="1">503</td><td align="char" char="." colspan="1" rowspan="1">53.5</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Guan</td><td align="left" colspan="1" rowspan="1">2021a</td><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">NTSCI</td><td align="left" colspan="1" rowspan="1">3468</td><td align="left" colspan="1" rowspan="1">1746</td><td align="left" colspan="1" rowspan="1">70<xref rid="TF11" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">2062</td><td align="left" colspan="1" rowspan="1">3468</td><td align="char" char="." colspan="1" rowspan="1">59.5</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Guan</td><td align="left" colspan="1" rowspan="1">2021b</td><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">934</td><td align="left" colspan="1" rowspan="1">664</td><td align="left" colspan="1" rowspan="1">63<xref rid="TF11" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" colspan="1" rowspan="1">626</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">934</td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">510</td><td align="left" colspan="1" rowspan="1">934</td><td align="char" char="." colspan="1" rowspan="1">54.6</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Guilcher</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">CAN</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">1842</td><td align="left" colspan="1" rowspan="1">1372</td><td align="left" colspan="1" rowspan="1">51<xref rid="TF11" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" colspan="1" rowspan="1">1143</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">6<xref rid="TF11" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" colspan="1" rowspan="1">1842</td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">644</td><td align="left" colspan="1" rowspan="1">1842</td><td align="char" char="." colspan="1" rowspan="1">35.0</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Wilkinson</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">RC</td><td align="left" colspan="1" rowspan="1">Trauma</td><td align="left" colspan="1" rowspan="1">7187</td><td align="left" colspan="1" rowspan="1">3849</td><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1">4031</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">7187</td><td align="left" colspan="1" rowspan="1">DD</td><td align="left" colspan="1" rowspan="1">3888</td><td align="left" colspan="1" rowspan="1">7187</td><td align="char" char="." colspan="1" rowspan="1">54.1</td><td align="left" colspan="1" rowspan="1">1597</td><td align="left" colspan="1" rowspan="1">320</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">424</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Total</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">-</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">-</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">-</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">-</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">52115</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">39643</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">-</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">18713</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">3905</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">-</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">27328</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">-</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">27677</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">50473</italic></td><td align="char" char="." colspan="1" rowspan="1"><italic toggle="yes">-</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">8318</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">5137</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">423</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">4819</italic></td></tr></tbody></table><table-wrap-foot><fn id="TF7"><p><italic toggle="yes">Note.</italic> Three studies (Margolis et al., 2014a, Margolis et al., 2014b &amp; Ullrich et al., 2014) described distinct sub-samples, and as such, this table details 41 cohorts from 38 studies.</p></fn><fn id="TF8"><p>Abbreviations: CR&#8201;=&#8201;chart review; CSS&#8201;=&#8201;cross-sectional survey; DD&#8201;=&#8201;dispensing database; MS&#8201;=&#8201;musculoskeletal pain; NeP&#8201;=&#8201;neuropathic pain; NI&#8201;=&#8201;nociceptive pain; NL&#8201;=&#8201;Netherlands; NR&#8201;=&#8201;not reported; NTSCI&#8201;=&#8201;non-traumatic spinal cord injury; OBS&#8201;=&#8201;observational study; PC&#8201;=&#8201;prospective cohort study; PD&#8201;=&#8201;prescription database; RC&#8201;=&#8201;retrospective cohort study; RCT&#8201;=&#8201;randomized controlled trial; SR&#8201;=&#8201;self-reported opioid use; TSI&#8201;=&#8201;time since injury (years).</p></fn><fn id="TF9"><label><sup>a</sup></label><p>SCI onset not specified (traumatic or non-traumatic), assumed to be a mixed cohort.</p></fn><fn id="TF10"><label><sup>b</sup></label><p>Reflective of total SCI cohort, which may not reflect full cohort in paper (e.g. excluding non-SCI control cohorts).</p></fn><fn id="TF11"><label><sup>c</sup></label><p>Reported in study as median.</p></fn><fn id="TF12"><label><sup>d</sup></label><p>Number not reported, <italic toggle="yes">n</italic> is calculated based on the reported proportion (i.e. the conservative calculated n was used when multiple numbers would equate to the same percentage).</p></fn><fn id="TF13"><label><sup>e</sup></label><p>Cervical injuries not reported in study, <italic toggle="yes">n</italic> is spinal cord injuries classified as tetraplegia.</p></fn><fn id="TF14"><label><sup>f</sup></label><p>Study reports on different durations/strengths of opioids (e.g. short-acting opioids), the highest prevalence is reported.</p></fn><fn id="TF15"><label><sup>g</sup></label><p>Based on current opioid use, as study captures self-reported use &#8216;ever&#8217; and &#8216;currently&#8217;.</p></fn><fn id="TF16"><label><sup>h</sup></label><p>Reported as categorical.</p></fn><fn id="TF17"><label><sup>i</sup></label><p>Thirty-seven percent (<italic toggle="yes">n</italic>&#8201;=&#8201;4964/13442) of the cohort were not able to be identified as traumatic or non-traumatic.</p></fn><fn id="TF18"><label><sup>j</sup></label><p><italic toggle="yes">n</italic>&#8201;=&#8201;1281 individuals excluded from prevalence as data is from two types of pharmacy dispensaries, and it is not certain the level of overlap.</p></fn></table-wrap-foot></table-wrap></p></sec><sec disp-level="2" id="S004-S2003"><title>Risk of bias</title><p>The risk of bias assessments and scores are presented in Supplementary Table 3. Risk of bias was determined to be low (20/38, 53%) or medium (16/38, 42%) across most studies. Two studies were determined to have a high risk of bias (<xref rid="CIT0040" ref-type="bibr">40</xref>, <xref rid="CIT0054" ref-type="bibr">54</xref>).</p></sec><sec disp-level="2" id="S004-S2004"><title>Meta-analyses</title><p>Details of the study samples included in the meta-analysis are provided in <xref rid="T0002" ref-type="table">Table 2</xref>. Three studies included propensity-score SCI matched populations, which were reported as two distinct subgroups of participants (<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0053" ref-type="bibr">53</xref>, <xref rid="CIT0062" ref-type="bibr">62</xref>). Consequently, there are 41 samples from the 38 studies included in the meta-analyses. The mean age of participants ranged from 35 to 75 years. The 41 cohorts included a total of 52,115 people with SCI (<xref rid="T0002" ref-type="table">Table 2</xref>). The largest sample consistent of 13,442 individuals from a national Veterans database in USA (<xref rid="CIT0048" ref-type="bibr">48</xref>), while the smallest sample was 19 people who had information extracted from medical records following attendance at an Ontario primary care clinic (<xref rid="CIT0058" ref-type="bibr">58</xref>).</p><sec disp-level="3" id="S004-S2004-S3001"><title>Overall pooled prevalence</title><p>The overall pooled prevalence of opioid use from the 38 studies was 39% (95% CI: 32&#8211;47%, <xref rid="T0003" ref-type="table">Table 3</xref>). Considerable between-study heterogeneity was evident with the prediction interval being two times wider than the 95% CI (prediction interval: 7&#8211;84%; <xref rid="F0002" ref-type="fig">Figure 2</xref>). This suggests a high degree of variability or uncertainty in the estimated prevalence of opioid use across the different studies.
<fig position="float" id="F0002" orientation="portrait"><label>Figure 2</label><caption><p>Meta-analysis of prevalence of opioids among people with SCI, stratified according to opioid context (charted medications, dispensed medications, prescribed medications, self-reported use) and ordered by year of publication. CI, confidence interval.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="YSCM_A_2319384_F0002_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="YSCM_A_2319384_F0002_PB.jpg"/></alternatives></fig>
<table-wrap position="float" id="T0003" orientation="portrait"><label>Table 3</label><caption><p>Meta-analysis results from studies reporting opioids in the SCI population.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="1" rowspan="1">Prevalence of</th><th align="center" colspan="1" rowspan="1">Number of cohorts*</th><th align="center" colspan="1" rowspan="1">Sample size</th><th colspan="4" align="center" rowspan="1">Random effects</th></tr><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">Prevalence (95% CI)</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">I</italic><sup>2</sup></th><th align="center" colspan="1" rowspan="1">&#964;<sup>2</sup></th><th align="center" colspan="1" rowspan="1">95% prediction interval</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">All non-overlapping cohorts</td><td align="left" colspan="1" rowspan="1">41 (from 38 studies)</td><td align="left" colspan="1" rowspan="1">50,473</td><td align="char" char="(" colspan="1" rowspan="1">39% (32&#8211;47)</td><td align="left" colspan="1" rowspan="1">99%</td><td align="char" char="." colspan="1" rowspan="1">1.06</td><td align="left" colspan="1" rowspan="1">7&#8211;84%</td></tr><tr><td align="left" colspan="1" rowspan="1">Excluding studies with high risk of bias</td><td align="left" colspan="1" rowspan="1">39 (from 36 studies)</td><td align="left" colspan="1" rowspan="1">50,350</td><td align="char" char="(" colspan="1" rowspan="1">41% (33&#8211;49)</td><td align="left" colspan="1" rowspan="1">99%</td><td align="char" char="." colspan="1" rowspan="1">1.00</td><td align="left" colspan="1" rowspan="1">8&#8211;84%</td></tr><tr><td align="left" colspan="1" rowspan="1">Opioid context</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="(" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Charted medications</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">931</td><td align="char" char="(" colspan="1" rowspan="1">31% (20&#8211;45)</td><td align="left" colspan="1" rowspan="1">95%</td><td align="char" char="." colspan="1" rowspan="1">0.47</td><td align="left" colspan="1" rowspan="1">5&#8211;78%</td></tr><tr><td align="left" colspan="1" rowspan="1">Dispensed medications</td><td align="left" colspan="1" rowspan="1">14 (from 11 studies)</td><td align="left" colspan="1" rowspan="1">38,903</td><td align="char" char="(" colspan="1" rowspan="1">59% (49&#8211;69)</td><td align="left" colspan="1" rowspan="1">99%</td><td align="char" char="." colspan="1" rowspan="1">0.65</td><td align="left" colspan="1" rowspan="1">19&#8211;90%</td></tr><tr><td align="left" colspan="1" rowspan="1">Prescribed medications</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">7519</td><td align="char" char="(" colspan="1" rowspan="1">68% (67&#8211;70)</td><td align="left" colspan="1" rowspan="1">45%</td><td align="char" char="." colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">67&#8211;70%</td></tr><tr><td align="left" colspan="1" rowspan="1">Self-reported use</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">3120</td><td align="char" char="(" colspan="1" rowspan="1">26% (20&#8211;34)</td><td align="left" colspan="1" rowspan="1">93%</td><td align="char" char="." colspan="1" rowspan="1">0.59</td><td align="left" colspan="1" rowspan="1">6&#8211;65%</td></tr><tr><td align="left" colspan="1" rowspan="1">Prevalence type</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="(" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Period prevalence</td><td align="left" colspan="1" rowspan="1">25 (from 22 studies)</td><td align="left" colspan="1" rowspan="1">48,099</td><td align="char" char="(" colspan="1" rowspan="1">51% (42&#8211;60)</td><td align="left" colspan="1" rowspan="1">99%</td><td align="char" char="." colspan="1" rowspan="1">0.74</td><td align="left" colspan="1" rowspan="1">15&#8211;87%</td></tr><tr><td align="left" colspan="1" rowspan="1">Point prevalence</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">1689</td><td align="char" char="(" colspan="1" rowspan="1">25% (18&#8211;32)</td><td align="left" colspan="1" rowspan="1">87%</td><td align="char" char="." colspan="1" rowspan="1">0.33</td><td align="left" colspan="1" rowspan="1">8&#8211;56%</td></tr><tr><td align="left" colspan="1" rowspan="1">Not reported</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">685</td><td align="char" char="(" colspan="1" rowspan="1">18% (8&#8211;38)</td><td align="left" colspan="1" rowspan="1">96%</td><td align="char" char="." colspan="1" rowspan="1">1.17</td><td align="left" colspan="1" rowspan="1">1&#8211;91%</td></tr><tr><td align="left" colspan="1" rowspan="1">Time since injury</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="(" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">1 year</td><td align="left" colspan="1" rowspan="1">10 (from 8 studies)</td><td align="left" colspan="1" rowspan="1">21,826</td><td align="char" char="(" colspan="1" rowspan="1">65% (53&#8211;76)</td><td align="left" colspan="1" rowspan="1">99%</td><td align="char" char="." colspan="1" rowspan="1">0.64</td><td align="left" colspan="1" rowspan="1">21&#8211;93%</td></tr><tr><td align="left" colspan="1" rowspan="1">2&#8211;10 years</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">2883</td><td align="char" char="(" colspan="1" rowspan="1">29% (19&#8211;43)</td><td align="left" colspan="1" rowspan="1">97%</td><td align="char" char="." colspan="1" rowspan="1">0.41</td><td align="left" colspan="1" rowspan="1">4&#8211;80%</td></tr><tr><td align="left" colspan="1" rowspan="1">10&#8211;15 years</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">801</td><td align="char" char="(" colspan="1" rowspan="1">28% (13&#8211;52)</td><td align="left" colspan="1" rowspan="1">96%</td><td align="char" char="." colspan="1" rowspan="1">1.02</td><td align="left" colspan="1" rowspan="1">0&#8211;98%</td></tr><tr><td align="left" colspan="1" rowspan="1">Over 15 years</td><td align="left" colspan="1" rowspan="1">11 (from 10 studies)</td><td align="left" colspan="1" rowspan="1">4343</td><td align="char" char="(" colspan="1" rowspan="1">30% (22&#8211;39)</td><td align="left" colspan="1" rowspan="1">96%</td><td align="char" char="." colspan="1" rowspan="1">0.48</td><td align="left" colspan="1" rowspan="1">8&#8211;69%</td></tr><tr><td align="left" colspan="1" rowspan="1">Not reported or listed categorically</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">20,620</td><td align="char" char="(" colspan="1" rowspan="1">35% (24&#8211;49)</td><td align="left" colspan="1" rowspan="1">99%</td><td align="char" char="." colspan="1" rowspan="1">0.85</td><td align="left" colspan="1" rowspan="1">6&#8211;83%</td></tr><tr><td align="left" colspan="1" rowspan="1">Opioids by length of mechanistic action</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="(" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Short-acting opioids</td><td align="left" colspan="1" rowspan="1">7 (from 5 studies)</td><td align="left" colspan="1" rowspan="1">10,157</td><td align="char" char="(" colspan="1" rowspan="1">55% (35&#8211;74)</td><td align="left" colspan="1" rowspan="1">100%</td><td align="char" char="." colspan="1" rowspan="1">1.23</td><td align="left" colspan="1" rowspan="1">6&#8211;96%</td></tr><tr><td align="left" colspan="1" rowspan="1">Long-acting opioids</td><td align="left" colspan="1" rowspan="1">7 (from 5 studies)</td><td align="left" colspan="1" rowspan="1">10,157</td><td align="char" char="(" colspan="1" rowspan="1">17% (11&#8211;25)</td><td align="left" colspan="1" rowspan="1">99%</td><td align="char" char="." colspan="1" rowspan="1">0.38</td><td align="left" colspan="1" rowspan="1">4-54%</td></tr></tbody></table><table-wrap-foot><fn id="TF19"><p><italic toggle="yes">Note.</italic> The number of cohorts does not directly correlate to the number of studies as three studies report on discrete propensity-score matched cohorts (<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0053" ref-type="bibr">53</xref>, <xref rid="CIT0062" ref-type="bibr">62</xref>). If the number of studies is not specified, the number of cohorts is equivalent to the number of studies.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec disp-level="2" id="S004-S2005"><title>Sensitivity analysis</title><p>The sensitivity analysis identified no change in the pooled prevalence of opioid use when the two studies with high risk of bias were removed (pooled prevalence: 41%; 95% CI: 33&#8211;49, prediction interval: 8&#8211;84%). There was also no difference in the overall pooled prevalence based on the leave-one-out approach (Supplementary Figure 4).</p><sec disp-level="3" id="S004-S2005-S3001"><title>Subgroup analysis</title><p>Subgroup analyses were conducted for four variables, with findings presented in <xref rid="T0003" ref-type="table">Table 3</xref>.</p><p><italic toggle="yes">Pooled prevalence by opioid data collection method</italic>. There was considerable variation in the prevalence estimates when comparing the data collection methods for capturing opioid use (<xref rid="F0002" ref-type="fig">Figure 2</xref>, <xref rid="T0003" ref-type="table">Table 3</xref>). The pooled prevalence of opioid use for prescribing data was highest at 68% (95% CI: 67&#8211;70; <italic toggle="yes">I</italic><sup>2&#8201;</sup>=&#8201;45%, <italic toggle="yes">&#964;</italic><sup>2&#8201;</sup>=&#8201;0), and lowest for self-reported opioid use at 26% (95% CI: 20&#8211;34, <italic toggle="yes">I</italic><sup>2&#8201;</sup>=&#8201;93%, <italic toggle="yes">&#964;</italic><sup>2&#8201;</sup>=&#8201;0.59, prediction interval: 6&#8211;65%).</p><p><italic toggle="yes">Pooled prevalence by prevalence type</italic>. The pooled period prevalence of opioid use was 51% (95% CI: 46&#8211;60; prediction interval: 15&#8211;87%). The pooled point prevalence of opioid use was lower at 25% (95% CI: 18&#8211;32; prediction interval: 8&#8211;56) (<xref rid="T0003" ref-type="table">Table 3</xref>).</p><p><italic toggle="yes">Pooled prevalence by time since injury.</italic> The pooled prevalence of opioid use was highest for the first year following SCI at 65% (95% CI: 53&#8211;76; prediction interval: 21&#8211;93%). Prevalence for the periods of 2&#8211;10 years; 10&#8211;15 years and over 15 years since injury remained consistent and was less than half the prevalence in the first-year post-injury (<xref rid="T0003" ref-type="table">Table 3</xref>). The pooled prevalence for the 11 studies where time since injury was not specified was 35% (95% CI: 24&#8211;19; prediction interval: 6&#8211;83%).</p><p><italic toggle="yes">Pooled prevalence of opioids by duration of action.</italic> Five studies reported opioids categorized into duration of action, specifically short- and long-acting (<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0042" ref-type="bibr">42</xref>, <xref rid="CIT0046" ref-type="bibr">46</xref>, <xref rid="CIT0053" ref-type="bibr">53</xref>, <xref rid="CIT0053" ref-type="bibr">53</xref>). The pooled prevalence was 55% (95% CI, 35&#8211;74, prediction interval: 6&#8211;96%) for short-acting opioids and 17% (95% CI, 11&#8211;25, prediction interval: 4&#8211;54%) for long-acting opioids (<xref rid="F0003" ref-type="fig">Figure 3</xref>; <xref rid="T0003" ref-type="table">Table 3</xref>). High heterogeneity was also evident, with prediction intervals 2&#8211;4 times wider than the 95% confidence intervals. A sixth study also reported on duration of action, however, this included a more complex classification of opioids into 8 distinct categories by dose and duration of action. These categories were not able to be collapsed into short- and long-acting categories and were excluded from this subgroup analysis. The 8 classification categories from this paper were: short-term low dose long-acting opioids (81.8%), long-term low dose long-acting opioids (10.2%), short-term high dose long-acting opioids (1.4%), long-term high dose long-acting opioids (6.6%), short-term low dose short-acting opioids (59.4%), long-term low dose short-acting opioids (40.6%), and short- and long-term high dose short-acting opioids (both 0%) (<xref rid="CIT0013" ref-type="bibr">13</xref>).
<fig position="float" id="F0003" orientation="portrait"><label>Figure 3</label><caption><p>Forest plot of meta-analysis for studies that report (A) short-acting and (B) long-acting opioids. CI, confidence interval.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="YSCM_A_2319384_F0003_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="YSCM_A_2319384_F0003_PB.jpg"/></alternatives></fig></p><p><xref rid="F0002" ref-type="fig">Figure 2</xref> shows studies plotted by year of publication, as a proxy for the chronological order of the data, which shows no clear pattern. Year of data collection was not considered as this was unreported in 21% (8/38) of studies (see <xref rid="T0001" ref-type="table">Table 1</xref>). Based on the high heterogeneity (prediction intervals for subgroups being up to 4 times wider than the 95% CIs) and the smaller number of included studies, a meta-regression was not completed.</p></sec></sec><sec disp-level="2" id="S004-S2006"><title>Opioid dosage</title><p>Mean opioid dose across studies was not able to be determined, as it was not reported in 95% (37/39) of studies. DiPiro <italic toggle="yes">et al.</italic> report a mean daily morphine milligram equivalents (MME) of 41&#8201;&#177;&#8201;70 (range&#8201;=&#8201;0.17&#8211;750) for 503 individuals with mixed onset of SCI (<xref rid="CIT0039" ref-type="bibr">39</xref>)<italic toggle="yes">.</italic> The second study including dose reports a median daily dose of 32.6&#8197;mg (interquartile range [IQR], 19.3, 87) MME for 1842 individuals with traumatic SCI (<xref rid="CIT0046" ref-type="bibr">46</xref>). A further three studies included categorized opioid dose within their methods. This included varying classifications of high opioid dose:&#8201;&#8805;&#8201;120&#8197;mg/day (<xref rid="CIT0013" ref-type="bibr">13</xref>), &gt;&#8201;225&#8197;mg/day (<xref rid="CIT0034" ref-type="bibr">34</xref>), while Guilcher <italic toggle="yes">et al.</italic> defined high-dose use as individuals with &#8805;90&#8197;mg/day for &#8805;90 days (<xref rid="CIT0046" ref-type="bibr">46</xref>).</p></sec><sec disp-level="2" id="S004-S2007"><title>Adverse events relating to opioid use</title><p>Four studies (11%) identified adverse outcomes relating to opioid use (full details in Supplementary Table 5). Carbone <italic toggle="yes">et al.</italic> found a positive relationship between opioid use and incidence of lower limb fractures in a cohort of male veterans with traumatic SCI (hazard ratio: 1.82, 95% CI, 1.59&#8211;2.09) (<xref rid="CIT0034" ref-type="bibr">34</xref>). Two studies identified associations between opioid use and hormone levels in male only chronic (&gt;2 years) SCI populations: biochemical androgen deficiency among a cohort of 319 (<xref rid="CIT0035" ref-type="bibr">35</xref>) and lower serum testosterone levels among 60 male Veterans (<xref rid="CIT0040" ref-type="bibr">40</xref>). Neither study was examined beyond the univariate level. A 2021 study explored associations between opioid analgesics and measures of cognitive performance in cohort of 173 individuals with mixed aetiology SCI and identified poorer outcomes for those on opioids in five of the nine cognitive measures (e.g. verbal fluency, working memory) (<xref rid="CIT0033" ref-type="bibr">33</xref>).</p><sec disp-level="3" id="S004-S2007-S3001"><title>Perceived effectiveness of opioids</title><p>Among the 18 studies that captured self-reported opioid use; only five also collected measures of <italic toggle="yes">effectiveness</italic> or <italic toggle="yes">helpfulness</italic> of opioids (<xref rid="CIT0037" ref-type="bibr">37</xref>, <xref rid="CIT0049" ref-type="bibr">49</xref>, <xref rid="CIT0060" ref-type="bibr">60</xref>, <xref rid="CIT0063" ref-type="bibr">63</xref>, <xref rid="CIT0065" ref-type="bibr">65</xref>). Each study used a separate measure to capture <italic toggle="yes">effectiveness</italic>. Despite this, opioids were often perceived to be the most effective method for pain relief among the pharmaceutical and non-pharmaceutical approaches investigated. Cardenas and Jensen used a 10-point scale to measure pain relief, ranging from 0 (no relief) to 10 (complete relief), where opioids offered the highest level of relief among the 10 various medication groupings (<xref rid="CIT0037" ref-type="bibr">37</xref>). Another study using a similar 5-point Likert scale from 1 (not at all helpful) to 5 (extremely helpful) and also found opioids to be the highest rated medication to help with pain (<xref rid="CIT0063" ref-type="bibr">63</xref>). Heutink and colleagues used a 3-item response to capture effectiveness of current treatments (not at all helpful; somewhat; to a large extent), where opioids had the highest rating among the six medication groups for being helpful &#8216;to a large extent&#8217; (<xref rid="CIT0049" ref-type="bibr">49</xref>). Tsai and colleagues measured helpfulness of treatments using a simple &#8216;no&#8217; or &#8216;yes&#8217; response, where opioids were the highest rated treatment among a list of twelve pharmaceutical and non-pharmaceutical approaches (e.g. heat therapy, massage) (<xref rid="CIT0060" ref-type="bibr">60</xref>). The fifth study used a 5-point response to measure the perceived effectiveness of treatments (response options: worse; no effect; slightly better; considerably better; pain free) (<xref rid="CIT0065" ref-type="bibr">65</xref>). Only four medications were rated by participants as contributing to being pain free, where opioids had the highest pain-free rating (<xref rid="CIT0065" ref-type="bibr">65</xref>). For full details of measures and outcomes for effectiveness, see Supplementary Table 6.</p></sec></sec><sec disp-level="2" id="S004-S2008"><title>Factors associated with opioid use</title><p>Five studies included models of personal characteristics that were associated with opioid use (see Supplementary Table 7) (<xref rid="CIT0039" ref-type="bibr">39</xref>, <xref rid="CIT0043" ref-type="bibr">43</xref>, <xref rid="CIT0044" ref-type="bibr">44</xref>, <xref rid="CIT0046" ref-type="bibr">46</xref>, <xref rid="CIT0052" ref-type="bibr">52</xref>). Studies were varied in relation to the population considered (e.g. traumatic only (<xref rid="CIT0043" ref-type="bibr">43</xref>, <xref rid="CIT0046" ref-type="bibr">46</xref>), non-traumatic only (<xref rid="CIT0044" ref-type="bibr">44</xref>), or a mixed cohort (<xref rid="CIT0039" ref-type="bibr">39</xref>, <xref rid="CIT0052" ref-type="bibr">52</xref>)); the outcome variable (e.g. dichotomized opioid use or chronic opioid use); and the number and type of variables considered (with modeling exploring association between 4 and 12 variables (<xref rid="CIT0039" ref-type="bibr">39</xref>, <xref rid="CIT0043" ref-type="bibr">43</xref>); Supplementary Table 7). Age, sex and time since injury were important across multiple studies (<xref rid="CIT0039" ref-type="bibr">39</xref>, <xref rid="CIT0043" ref-type="bibr">43</xref>, <xref rid="CIT0044" ref-type="bibr">44</xref>, <xref rid="CIT0046" ref-type="bibr">46</xref>). However, these studies were inconsistent in the direction of an effect for sex and included inconsistent formats of variables (e.g. age included as continuous or categorical). They also exclusively represented samples of people with SCI in Canada (<italic toggle="yes">n&#8201;</italic>=&#8201;3) or the USA (<italic toggle="yes">n&#8201;</italic>=&#8201;2). Other variables, for example, chronic obstructive pulmonary disease or osteoarthritis (<xref rid="CIT0043" ref-type="bibr">43</xref>), and measures of functional capacity (<xref rid="CIT0044" ref-type="bibr">44</xref>), were only considered in a single study, and their level of importance was even less certain. Given the heterogeneity across models used and the variables considered, a meta-analysis for factors related to opioid use was not conducted.</p></sec></sec><sec sec-type="discussion" disp-level="1" id="S005"><title>Discussion</title><p>This is the first systematic review and meta-analysis to be conducted on the prevalence of opioid use in people with SCI living in the community. The meta-analysis identified an overall prevalence of opioid use of 39% among adult SCI populations, with extremely high heterogeneity, evidenced by a prediction interval two times wider than the 95% confidence interval (<xref rid="F0002" ref-type="fig">Figure 2</xref>; <xref rid="T0003" ref-type="table">Table 3</xref>). In the case of wide prediction intervals, as in the current study, caution is needed when interpreting findings of meta-analyses (<xref rid="CIT0067" ref-type="bibr">67</xref>). Consequently, subgroup analyses reflecting the data collection method offered a better understanding of the prevalence of opioid use. Secondary outcomes were seldom reported, with factors associated with opioid use and adverse events reported in less than 15% of studies (Supplementary tables 5 and 6). This review highlights a clear need for additional studies and stronger, more consistent reporting of main outcomes and injury characteristics to enable better understanding of opioid use in this high-risk population.</p><p>A major theme evident from this review was the considerable variability and lack of consistency in the reporting of methodological and injury characteristics. Prevalence type (point or period prevalence) was unreported in 13% of studies, while 3 of the 11 studies reporting period prevalence did not specify the period for which they measured opioid use (<xref rid="T0001" ref-type="table">Table 1</xref>). The recruitment or observation period was unreported in approximately 20% of studies (<xref rid="T0001" ref-type="table">Table 1</xref>), often making it difficult to determine whether populations across the included studies were distinct. Rates of reporting of SCI-specific injury characteristics were highly varied, including high rates of missing details for basic SCI variables. For example, injury aetiology not specified in 37% of studies (<xref rid="T0001" ref-type="table">Table 1</xref>). There has long since been a recommendation for standardization regarding the reporting of characteristics for samples of people with SCI (<xref rid="CIT0068" ref-type="bibr">68</xref>). Yet even the more recent articles included in this review were not consistent with these standards. These reporting deficits limit the generalizability of findings and highlight the need for standardized and clearer reporting.</p><p>Subgroup analysis for opioid context followed a clear pattern of higher proportions prescribed or dispensed opioids (59&#8211;68%), compared to those who self-reported opioid use (26%, <xref rid="F0002" ref-type="fig">Figure 2</xref>). This was mostly consistent with the findings regarding prevalence type. Period prevalence (51%, <xref rid="T0003" ref-type="table">Table 3</xref>) which was typically obtained through prescribing or dispensing data was higher than point prevalence (25%, <xref rid="T0003" ref-type="table">Table 3</xref>), which was captured through self-reporting. Dispensing and prescribing data can routinely be captured across geographical catchment areas, and in the current study, it accounted for nearly three quarters of the total pooled participants. As such, this data collection method is often ideal for ascertaining population-level trends. Such data monitoring sources can directly influence clinical practice and policy (<xref rid="CIT0069" ref-type="bibr">69</xref>), for example, when escalations in medication prescribing are detected. Yet, the difference in prevalence between opioids dispensed and those reported as being taken (a difference of 33%) has implications about the potential overestimation of opioid use among people with SCI. While self-reporting may account for underreporting of opioid use in surveys and dispensing data does not directly relate to opioids that are consumed, the wide difference brings into question the reliability of the data monitoring information compared to what may actually be happening. This again reiterates caution when interpreting findings from large datasets that may overestimate opioid use.</p><p>Secondary outcomes and opioid context were also rarely reported. Opioid dose was unreported in 95% of studies. This was despite pharmaceutical data or medical records accounting for approximately half of the data sources of included studies. When opioid dose was reported, this was typically considered over the duration of the study period (any opioid use over 12 months) and prevalence over smaller increments (e.g. 30-day intervals) were not considered. The remaining studies reported dose using varying cut points for what they considered &#8216;high&#8217; dose opioids (Supplementary table 5), again making comparisons difficult. The effectiveness of opioids was also seldom considered, and for the five papers that did consider opioid efficacy for pain relief, each study utilized a different measure. Adverse effects were also inconsistently reported. For example, a common side effect of opioids is constipation (<xref rid="CIT0070" ref-type="bibr">70</xref>), and people with SCI are a population known to experience high rates of bowel problems (<xref rid="CIT0008" ref-type="bibr">8</xref>). Yet bowel functioning was not among the reported adverse effects, again suggesting opioids as an under-researched area among this population. For the secondary outcome of factors associated with opioid use, studies also differed in what variables they considered in their statistical modeling. As such, it was not possible to provide any clear indication of which characteristics were important when considered collectively. Studies that can capture full opioid details (e.g. pharmaceutical data that includes detail of medication dose and dispensing dates) should focus on presenting more in-depth opioid information to help contextualize opioid use among people with SCI. There is also a need for further and more robust investigation into associations between characteristics and opioid use as a means of identifying subgroups within SCI populations who may be at greater risk of opioid-related harms.</p><p>The heterogeneity and imprecision of prevalence in the current study make it difficult to make clinical inferences about opioid use among SCI populations. However, the pooled prevalence for self-reported opioid use (28%, <xref rid="F0002" ref-type="fig">Figure 2</xref>) was similar to a recent meta-analysis on opioid use among chronic non-cancer pain (27%, 95% CI, 23&#8211;31) (<xref rid="CIT0071" ref-type="bibr">71</xref>). In the current review, two-thirds of included studies had cohorts with mixed aetiology of SCI, yet opioid use was rarely contextualized to injury aetiology. Of the remaining studies that considered aetiology-specific populations, only one study focused on non-traumatic SCI, compared to a quarter of studies that focused on traumatic SCI. It is well recognized that characteristics vary within SCI populations, particularly in relation to injury aetiology. Traumatic SCI is historically more common among younger and male populations, while those with non-traumatic onset are often older and frequently considered medically complex irrespective of their SCI (<xref rid="CIT0072" ref-type="bibr">72&#8211;74</xref>). Such differences are likely to have an impact on the prevalence of opioids dispensed to or used by these subgroups. Yet, the lack of reporting by aetiology type and a reduced focus on non-traumatic cohorts makes such comparisons unfeasible based on currently available studies.</p><p>This systematic review presents a rigorous exploration of opioid use in people with SCI living in the community; and in doing so acknowledges several practical considerations for moving forward. Firstly, caution should be exercised when interpreting studies reporting opioid use among SCI populations given the lack of generalizability, and in consideration of the significant heterogeneity demonstrated by the prediction intervals. Secondly, future studies focused on adults with SCI should ensure a standard practice of reporting injury-based characteristics for contextualizing opioid uses (and other outcomes). Recommended variables to include for reporting generally among studies, as well as in SCI or opioid-focused study are listed in <xref rid="T0004" ref-type="table">Table 4</xref>. Thirdly, in consideration of the well-documented characteristic differences within SCI populations (e.g. in relation to SCI aetiology), greater emphasis needs to be given to subpopulations when studies include SCI of mixed aetiology. Fourthly, future studies need to facilitate a more in-depth picture of opioid use, including dose and prevalence over shorter increments given the fluctuation of pain, and in consideration of opioids being intended for shorter-term use.
<table-wrap position="float" id="T0004" orientation="portrait"><label>Table 4</label><caption><p>Recommended variables for reporting.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" span="1"/><col width="1*" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="1" rowspan="1">Focus</th><th align="center" colspan="1" rowspan="1">Information for reporting</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">General methods information</td><td align="left" colspan="1" rowspan="1">Recruitment and observation period</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Year of data collection</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Prevalence type: point or period prevalence (including specification of the period)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Age and sex</td></tr><tr><td align="left" colspan="1" rowspan="1">Information for studies that include people with SCI</td><td align="left" colspan="1" rowspan="1">Aetiology: traumatic, non-traumatic or mixed aetiology (including specific numbers when reported as mixed populations)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Neurological level of injury: tetraplegia vs. paraplegia, and specification of SCI level if possible (e.g. C1&#8211;4, C5&#8211;8)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Degree of impairment as complete vs. incomplete SCI, or AIS Grading A&#173;&#8211;E, if known</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Time since injury</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Type of SCI-specific pain classification (ISCIP Classification)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Presence of other major injuries, illnesses or disease at the time of SCI that may also result in chronic pain</td></tr><tr><td align="left" colspan="1" rowspan="1">Information relating to opioids</td><td align="left" colspan="1" rowspan="1">Prevalence of opioids</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Opioid data collection method</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Context of pain</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Duration of opioid use (e.g. number of days of prescription coverage)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Dose of opioids, including changes over time, where possible</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Type of opioid (e.g. long vs. short-acting opioids)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">For studies focusing on the immediate post-injury period, opioid use during initial inpatient rehabilitation</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Side effects relevant to SCI populations: including bowel and bladder problems, cognitive and behavioral side effects and respiratory problems.</td></tr></tbody></table><table-wrap-foot><fn id="TF20"><p>Abbreviations: AIS&#8201;=&#8201;American Spinal Injury Association (ASIA) Impairment Scale; ISCIP&#8201;=&#8201;International Spinal Cord Injury Pain; SCI&#8201;=&#8201;spinal cord injury.</p></fn></table-wrap-foot></table-wrap></p><p><italic toggle="yes">Study limitations.</italic> This systematic review is not without limitations. We acknowledge that despite a comprehensive search strategy, relevant articles published in non-English languages may have been missed. Another primary limitation is the smaller number of included studies and high heterogeneity across study populations, which prevented further explorations into underlying reasons for variations in prevalence. This high heterogeneity could be a contraindicator for inclusion of a meta-analysis. However, as with other studies that experienced high levels of heterogeneity (<xref rid="CIT0001" ref-type="bibr">1</xref>), the authors felt that completion of a meta-analysis was appropriate both in consideration of the analysis approach which focused on opioids by context; and in the broader concept of highlighting the importance of further research needed in this space.</p><p>The scope of this review was limited to studies focusing on prevalence of prescription opioids; and the misuse of prescription opioids, and other illegal narcotics were not considered. Consequently, this review does not capture the full breadth of opioid issues or harms among SCI populations. A noticeable limitation is the heterogeneity within the SCI populations among the included studies, largely influenced by the diverse participant eligibility criteria, limiting the generalizability of study findings. Data for approximately 70% of studies originated from North America, creating a strong representation for veteran populations and individuals with varying health insurance eligibilities or coverage (<xref rid="T0001" ref-type="table">Table 1</xref>). This largely limits the generalizability of findings for populations outside of North America.</p><sec disp-level="2" id="S005-S2001"><title>Conclusion</title><p>This study identified a pooled prevalence of opioid use among adults with SCI living in the community, demonstrating high heterogeneity across the included study populations. Despite many studies reporting prevalence of opioid use, the wide variation in populations included means that much remains to be elucidated about who uses opioids after SCI, for low long and at what dose. Additionally, opioid context and secondary outcomes were rarely reported, indicating a clear need for additional studies in a population at greater risk of experiencing opioid-related adverse effects.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM7137" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplementary materials.docx</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="YSCM_A_2319384_SM7137.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec disp-level="1" id="S006"><title>Disclaimer statements</title><p><bold>Funding</bold> This review was not funded.</p><p><bold>Conflict of interest</bold> The authors declare they have no competing interests.</p></sec><sec sec-type="supplementary-material" disp-level="1" id="S007"><title>Supplemental data</title><p>Supplemental data for this article can be accessed online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1080/10790268.2024.2319384" ext-link-type="doi">https://doi.org/10.1080/10790268.2024.2319384</ext-link>.</p></sec><ref-list><title>
References
</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hunt</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Moman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Covington</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mustafa</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Murad</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Hooten</surname><given-names>WM.</given-names></string-name></person-group><article-title>Prevalence of chronic pain after spinal cord injury: a systematic review and meta-analysis</article-title>. <source>Reg Anesth Pain Med</source><year>2021</year>;<volume>46</volume>: <fpage>328</fpage>&#8211;<lpage>336</lpage>. doi:<pub-id pub-id-type="doi">10.1136/rapm-2020-101960</pub-id>.<pub-id pub-id-type="pmid">33408161</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ataoglu</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tiftik</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kara</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tunc</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ersoz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Akkus</surname><given-names>S.</given-names></string-name></person-group><article-title>Effects of chronic pain on quality of life and depression in patients with spinal cord injury</article-title>. <source>Spinal Cord</source><year>2013</year>;<volume>51</volume>:<fpage>23</fpage>&#8211;<lpage>26</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2012.51</pub-id>.<pub-id pub-id-type="pmid">22547044</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Widerstrom-Noga</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Felipe-Cuervo</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yezierski</surname><given-names>RP.</given-names></string-name></person-group><article-title>Chronic pain after spinal injury: Interference with sleep and daily activities</article-title>. <source>Arch Phys Med Rehabil</source><year>2001</year>;<volume>82</volume>:<fpage>1571</fpage>&#8211;<lpage>1577</lpage>. doi:<pub-id pub-id-type="doi">10.1053/apmr.2001.26068</pub-id>.<pub-id pub-id-type="pmid">11689978</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Margolis</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Juneau</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sadosky</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cappelleri</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Bryce</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Nieshoff</surname><given-names>EC.</given-names></string-name></person-group><article-title>Health care resource utilization and medical costs of spinal cord injury with neuropathic pain in a commercially insured population in the United States</article-title>. <source>Arch Phys Med Rehabil</source><year>2014</year>;<volume>95</volume>:<fpage>2279</fpage>&#8211;<lpage>2287</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.apmr.2014.07.416</pub-id>.<pub-id pub-id-type="pmid">25159715</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krause</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Dismuke-Greer</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Reed</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C.</given-names></string-name></person-group><article-title>Employment status, hours working, and gainful earnings after spinal cord injury: Relationship with pain, prescription medications for pain, and nonprescription opioid use</article-title>. <source>Spinal Cord</source><year>2020</year>;<volume>58</volume>:<fpage>275</fpage>&#8211;<lpage>283</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41393-019-0374-1</pub-id>.<pub-id pub-id-type="pmid">31676870</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Chou</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Deyo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Devine</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sullivan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jarvik</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Blazina</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Dana</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bougatsos</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>J.</given-names></string-name></person-group><article-title>The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain</article-title>. <source>Evid Rep Technol Assess (Full Rep</source>) <year>2014</year>:<fpage>1</fpage>&#8211;<lpage>219</lpage>. doi:<pub-id pub-id-type="doi">10.23970/AHRQEPCERTA218</pub-id>.<pub-id pub-id-type="pmid">30313000</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>McAnally</surname><given-names>HB.</given-names></string-name></person-group><source>Opioid dependence: A clinical and epidemiologic approach</source>. <edition>1st ed</edition>. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>; <year>2018</year>. doi:<pub-id pub-id-type="doi">10.1007/978-3-319-47497-7</pub-id>.</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Middleton</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Arora</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kifley</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Borg</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Tran</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Atresh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shetty</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nunn</surname><given-names>A</given-names></string-name></person-group>, <italic toggle="yes">et al</italic>. <article-title>Australian arm of the International Spinal Cord Injury (Aus-InSCI) Community Survey: 2. Understanding the lived experience in people with spinal cord injury</article-title>. <source>Spinal Cord</source><year>2022</year>;<volume>60</volume>:<fpage>1069</fpage>&#8211;<lpage>1079</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41393-022-00817-7</pub-id>.<pub-id pub-id-type="pmid">35705701</pub-id><pub-id pub-id-type="pmcid">PMC9712098</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kitzman</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Cecil</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kolpek</surname><given-names>JH.</given-names></string-name></person-group><article-title>The risks of polypharmacy following spinal cord injury</article-title>. <source>J Spinal Cord Med</source><year>2017</year>;<volume>40</volume>:<fpage>147</fpage>&#8211;<lpage>153</lpage>. doi:<pub-id pub-id-type="doi">10.1179/2045772314Y.0000000235</pub-id>.<pub-id pub-id-type="pmid">24970339</pub-id><pub-id pub-id-type="pmcid">PMC5430470</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mestre</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Alkon</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Salazar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ibarra</surname><given-names>A.</given-names></string-name></person-group><article-title>Spinal cord injury sequelae alter drug pharmacokinetics: An overview</article-title>. <source>Spinal Cord</source><year>2011</year>;<volume>49</volume>:<fpage>955</fpage>&#8211;<lpage>960</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2011.58</pub-id>.<pub-id pub-id-type="pmid">21625241</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bryce</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Biering-S&#248;rensen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Finnerup</surname><given-names>NB</given-names></string-name>, <string-name name-style="western"><surname>Cardenas</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Defrin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lundeberg</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Norrbrink</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Richards</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Siddall</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Stripling</surname><given-names>T</given-names></string-name></person-group>, <italic toggle="yes">et al</italic>. <article-title>International Spinal Cord Injury Pain Classification: part I. Background and description</article-title>. <source>Spinal Cord</source><year>2012</year>;<volume>50</volume>:<fpage>413</fpage>&#8211;<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2011.156</pub-id>.<pub-id pub-id-type="pmid">22182852</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Loh</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mirkowski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Agudelo</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Allison</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Benton</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bryce</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Guilcher</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jeji</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kras-Dupuis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kreutzwiser</surname><given-names>D</given-names></string-name></person-group>, <italic toggle="yes">et al</italic>. <article-title>The CanPain SCI clinical practice guidelines for rehabilitation management of neuropathic pain after spinal cord injury: 2021 update</article-title>. <source>Spinal Cord</source><year>2022</year>;<volume>60</volume>:<fpage>548</fpage>&#8211;<lpage>566</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41393-021-00744-z</pub-id>.<pub-id pub-id-type="pmid">35124700</pub-id><pub-id pub-id-type="pmcid">PMC9209331</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hand</surname><given-names>BN</given-names></string-name>, <string-name name-style="western"><surname>Krause</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Simpson</surname><given-names>KN.</given-names></string-name></person-group><article-title>Dose and duration of opioid use in propensity score-matched, privately insured opioid users with and without spinal cord injury</article-title>. <source>Arch Phys Med Rehabil</source><year>2018</year>;<volume>99</volume>:<fpage>855</fpage>&#8211;<lpage>861</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.apmr.2017.12.004</pub-id>.<pub-id pub-id-type="pmid">29307814</pub-id><pub-id pub-id-type="pmcid">PMC8042611</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>McLellan</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Cotto</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Karithanom</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>SRB.</given-names></string-name></person-group><article-title>Characteristics of opioid prescriptions in 2009</article-title>. <source>JAMA J Am Med Assoc</source><year>2011</year>;<volume>305</volume>:<fpage>1299</fpage>&#8211;<lpage>1301</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2011.401</pub-id>.<pub-id pub-id-type="pmcid">PMC3187622</pub-id><pub-id pub-id-type="pmid">21467282</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shoup</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Welter</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Binswanger</surname><given-names>IA</given-names></string-name>, <string-name name-style="western"><surname>Hess</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Dullenkopf</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Coker</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Berliner</surname><given-names>J.</given-names></string-name></person-group><article-title>Spinal cord injury and prescribed opioids for pain: a scoping review</article-title>. <source>Pain Med</source><year>2023</year>;<volume>24</volume>:<fpage>1138</fpage>&#8211;<lpage>1152</lpage>. doi:<pub-id pub-id-type="doi">10.1093/pm/pnad073</pub-id>.<pub-id pub-id-type="pmid">37280072</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Page</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Boutron</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Hoffmann</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Mulrow</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Shamseer</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tetzlaff</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Akl</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Brennan</surname><given-names>SE</given-names></string-name></person-group>,<italic toggle="yes">, et al</italic>. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source><volume>2021</volume>;<issue>372</issue>:<fpage>n71</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id>.<pub-id pub-id-type="pmcid">PMC8005924</pub-id><pub-id pub-id-type="pmid">33782057</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Tenny</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hoffman</surname><given-names>MR.</given-names></string-name></person-group> Prevalence [Internet]. StatPearls Publishing, Treasure Island (FL); 2022. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK430867/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK430867/</ext-link>.</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Clarivate</collab></person-group>. Endnote [Internet]. 2023 [cited 2023 Nov 15]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://endnote.com/" ext-link-type="uri">https://endnote.com/</ext-link>.</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Rayyan</collab></person-group>. Intelligent Systematic Review [Internet]. 2022 [cited 2023 Nov 15]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rayyan.ai/" ext-link-type="uri">https://www.rayyan.ai/</ext-link>.</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Microsoft 365</collab></person-group>. Microsoft Excel Spreadsheet Software [Internet]. [cited 2023 Oct 23]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.microsoft.com/en-au/microsoft-365/excel" ext-link-type="uri">https://www.microsoft.com/en-au/microsoft-365/excel</ext-link>.</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hoy</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Brooks</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Woolf</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Blyth</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>March</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bain</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Buchbinder</surname><given-names>R.</given-names></string-name></person-group><article-title>Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement</article-title>. <source>J Clin Epidemiol</source><year>2012</year>;<volume>65</volume>:<fpage>934</fpage>&#8211;<lpage>939</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jclinepi.2011.11.014</pub-id>.<pub-id pub-id-type="pmid">22742910</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>R Core Team</collab></person-group>. R: A language and environment for statistical computing. R Foundation for Statistical Computing [Internet]. Vienna, Austria; 2020. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R-project.org/</ext-link>.</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>R Studio</collab></person-group>. RStudio [Internet]. 2021. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rstudio.com/" ext-link-type="uri">https://www.rstudio.com/</ext-link>.</mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Schawarzer</surname><given-names>G.</given-names></string-name></person-group> Package &#8216;meta&#8217;: General Package for Meta-Analysis. 2024 [cited 2023 Oct 23]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cran.r-project.org/web/packages/meta/meta.pdf" ext-link-type="uri">https://cran.r-project.org/web/packages/meta/meta.pdf</ext-link>.</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>H.</given-names></string-name></person-group><article-title>Meta-analysis of proportions using generalized linear mixed models</article-title>. <source>Epidemiology</source><year>2020</year>;<volume>31</volume>:<fpage>713</fpage>&#8211;<lpage>717</lpage>. doi:<pub-id pub-id-type="doi">10.1097/EDE.0000000000001232</pub-id>.<pub-id pub-id-type="pmid">32657954</pub-id><pub-id pub-id-type="pmcid">PMC7398826</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schwarzer</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chemaitelly</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Abu-Raddad</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>R&#252;cker</surname><given-names>G.</given-names></string-name></person-group><article-title>Seriously misleading results using inverse of freeman-Tukey double arcsine transformation in meta-analysis of single proportions</article-title>. <source>Res Synth Methods</source><year>2019</year>;<volume>10</volume>:<fpage>476</fpage>&#8211;<lpage>483</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jrsm.1348</pub-id>.<pub-id pub-id-type="pmid">30945438</pub-id><pub-id pub-id-type="pmcid">PMC6767151</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>IntHout</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ioannidis</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Rovers</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Goeman</surname><given-names>JJ.</given-names></string-name></person-group><article-title>Plea for routinely presenting prediction intervals in meta-analysis</article-title>. <source>BMJ Open</source><year>2016</year>;<volume>6</volume>:<fpage>e010247</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2015-010247</pub-id>.<pub-id pub-id-type="pmcid">PMC4947751</pub-id><pub-id pub-id-type="pmid">27406637</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Metainf function</collab></person-group>. RDocumentation [Internet]. [cited 2023 Oct 30]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rdocumentation.org/packages/meta/versions/4.9-6/topics/metainf" ext-link-type="uri">https://www.rdocumentation.org/packages/meta/versions/4.9-6/topics/metainf</ext-link>.</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guilcher</surname><given-names>SJT</given-names></string-name>, <string-name name-style="western"><surname>Hogan</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>McCormack</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Calzavara</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Hitzig</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Packer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Lofters</surname><given-names>AK.</given-names></string-name></person-group><article-title>Prescription medications dispensed following a nontraumatic spinal cord dysfunction: a retrospective population-based study in Ontario, Canada</article-title>. <source>Spinal Cord</source><year>2021</year>;<volume>59</volume>:<fpage>132</fpage>&#8211;<lpage>140</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41393-020-0511-x</pub-id>.<pub-id pub-id-type="pmid">32665709</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>DiPiro</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Murday</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Krause</surname><given-names>JS.</given-names></string-name></person-group><article-title>Assessment of high-risk opioid use metrics among individuals with spinal cord injury: A brief report</article-title>. <source>J Spinal Cord Med</source><year>2023</year>;<volume>46</volume>:<fpage>687</fpage>&#8211;<lpage>691</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10790268.2022.2084931</pub-id>.<pub-id pub-id-type="pmid">37318872</pub-id><pub-id pub-id-type="pmcid">PMC10274556</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karran</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Fryer</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Middleton</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Moseley</surname><given-names>GL.</given-names></string-name></person-group><article-title>Pain and pain management experiences following spinal cord injury &#8211; a mixed methods study of Australian community-dwelling adults</article-title>. <source>Disabil Rehabil</source><year>2022</year>;<volume>45</volume>:<fpage>455</fpage>&#8211;<lpage>468</lpage>. doi:<pub-id pub-id-type="doi">10.1080/09638288.2022.2034994</pub-id>.<pub-id pub-id-type="pmid">35156498</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carlozzi</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Troost</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Singhal</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ehde</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Bakshi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Molton</surname><given-names>IR</given-names></string-name>, <string-name name-style="western"><surname>Miner</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Graves</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Kratz</surname>, <given-names>AL.</given-names></string-name></person-group><article-title>The Association Between Medication Use and Cognitive Performance in People With SCI</article-title>. <source>Rehabil Psychol</source><year>2021</year>;<volume>66</volume>:<fpage>541</fpage>&#8211;<lpage>549</lpage>. doi:<pub-id pub-id-type="doi">10.1037/rep0000412</pub-id>.<pub-id pub-id-type="pmid">34618512</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carbone</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Chin</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Svircev</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Hoenig</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Akhigbe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>FM.</given-names></string-name></person-group><article-title>The association of opioid use with incident lower extremity fractures in spinal cord injury</article-title>. <source>J Spinal Cord Med</source><year>2013</year>;<volume>36</volume>:<fpage>91</fpage>&#8211;<lpage>96</lpage>. doi:<pub-id pub-id-type="doi">10.1179/2045772312Y.0000000060</pub-id>.<pub-id pub-id-type="pmid">23809522</pub-id><pub-id pub-id-type="pmcid">PMC3595973</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Behnaz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Majd</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Radfar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ajami</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Qorbani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kokab</surname><given-names>A.</given-names></string-name></person-group><article-title>Prevalence of androgen deficiency in chronic spinal cord injury patients suffering from erectile dysfunction</article-title>. <source>Spinal Cord</source><year>2017</year>;<volume>55</volume>(<issue>12</issue>):<fpage>1061</fpage>&#8211;<lpage>1065</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2017.73</pub-id>.<pub-id pub-id-type="pmid">28631746</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Burke</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fullen</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Lennon</surname><given-names>O.</given-names></string-name></person-group><article-title>Pain profiles in a community dwelling population following spinal cord injury: A national survey</article-title>. <source>J Spinal Cord Med</source><year>2019</year>;<volume>42</volume>:<fpage>201</fpage>&#8211;<lpage>211</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10790268.2017.1351051</pub-id>.<pub-id pub-id-type="pmid">28738744</pub-id><pub-id pub-id-type="pmcid">PMC6419620</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cardenas</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Jensen</surname><given-names>MP.</given-names></string-name></person-group><article-title>Treatments for chronic pain in persons with spinal cord injury: A survey study</article-title>. <source>J Spinal Cord Med</source><year>2006</year>;<volume>29</volume>:<fpage>109</fpage>&#8211;<lpage>117</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10790268.2006.11753864</pub-id>.<pub-id pub-id-type="pmid">16739554</pub-id><pub-id pub-id-type="pmcid">PMC1864800</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cragg</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Haefeli</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jutzeler</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>R&#246;hrich</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Weidner</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Saur</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maier</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Kalke</surname><given-names>YB</given-names></string-name>, <string-name name-style="western"><surname>Schuld</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Curt</surname><given-names>A</given-names></string-name></person-group>, <italic toggle="yes">et al</italic>. <article-title>Effects of pain and pain management on motor recovery of spinal cord-injured patients: A longitudinal study</article-title>. <source>Neurorehabil Neural Repair</source><year>2016</year>;<volume>30</volume>:<fpage>753</fpage>&#8211;<lpage>761</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1545968315624777</pub-id>.<pub-id pub-id-type="pmid">26747127</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>DiPiro</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Murday</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Corley</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>DiPiro</surname><given-names>TV</given-names></string-name>, <string-name name-style="western"><surname>Krause</surname><given-names>JS.</given-names></string-name></person-group><article-title>Opioid Use Among individuals with spinal cord injury: Prevalence estimates based on state prescription drug monitoring program data</article-title>. <source>Arch Phys Med Rehabil</source><year>2021</year>;<volume>102</volume>:<fpage>828</fpage>&#8211;<lpage>834</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.apmr.2020.10.128</pub-id>.<pub-id pub-id-type="pmid">33227268</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Durga</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sepahpanah</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Regozzi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hastings</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Crane</surname><given-names>DA.</given-names></string-name></person-group><article-title>Prevalence of testosterone deficiency after spinal cord injury</article-title>. <source>PM&amp;R</source><year>2011</year>;<volume>3</volume>:<fpage>929</fpage>&#8211;<lpage>932</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pmrj.2011.07.008</pub-id>.<pub-id pub-id-type="pmid">22024324</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Finnerup</surname><given-names>NB</given-names></string-name>, <string-name name-style="western"><surname>Johannesen</surname><given-names>IL</given-names></string-name>, <string-name name-style="western"><surname>Sindrup</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Bach</surname><given-names>FW</given-names></string-name>, <string-name name-style="western"><surname>Jensen</surname><given-names>TS.</given-names></string-name></person-group><article-title>Pain and dysesthesia in patients with spinal cord injury: A postal survey</article-title>. <source>Spinal Cord</source><year>2001</year>;<volume>39</volume>:<fpage>256</fpage>&#8211;<lpage>262</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sj.sc.3101161</pub-id>.<pub-id pub-id-type="pmid">11438841</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gore</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brix Finnerup</surname><given-names>NB</given-names></string-name>, <string-name name-style="western"><surname>Sadosky</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tai</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Cappelleri</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Mardekian</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rice</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Nieshoff</surname><given-names>E.</given-names></string-name></person-group><article-title>Pain-related pharmacotherapy, healthcare resource use and costs in spinal cord injury patients prescribed pregabalin</article-title>. <source>Spinal Cord</source><year>2013</year>;<volume>51</volume>:<fpage>126</fpage>&#8211;<lpage>133</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2012.97</pub-id>.<pub-id pub-id-type="pmid">22945747</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guan</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Calzavara</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cadel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hogan</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>McCormack</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lofters</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Hitzig</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Guilcher</surname><given-names>SJT.</given-names></string-name></person-group><article-title>Indicators of publicly funded prescription opioid use among persons with traumatic spinal cord injury in Ontario, Canada</article-title>. <source>J Spinal Cord Med</source><year>2021</year>;<volume>46</volume>:<fpage>881</fpage>&#8211;<lpage>888</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10790268.2021.1969503</pub-id>.<pub-id pub-id-type="pmid">34698613</pub-id><pub-id pub-id-type="pmcid">PMC10653736</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guan</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Hogan</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Calzavara</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>McCormack</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lofters</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hitzig</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Packer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Guilcher</surname><given-names>SJT.</given-names></string-name></person-group><article-title>Prevalence of prescribed opioid claims among persons with nontraumatic spinal cord dysfunction in Ontario, Canada: a population-based retrospective cohort study</article-title>. <source>Spinal Cord</source><year>2021</year>;<volume>59</volume>:<fpage>512</fpage>&#8211;<lpage>519</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41393-020-00605-1</pub-id>.<pub-id pub-id-type="pmid">33495578</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guilcher</surname><given-names>SJT</given-names></string-name>, <string-name name-style="western"><surname>Hogan</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Calzavara</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hitzig</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Packer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lofters</surname><given-names>AK.</given-names></string-name></person-group><article-title>Prescription drug claims following a traumatic spinal cord injury for older adults: a retrospective population-based study in Ontario, Canada</article-title>. <source>Spinal Cord</source><year>2018</year>;<volume>56</volume>:<fpage>1059</fpage>&#8211;<lpage>1068</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41393-018-0174-z</pub-id>.<pub-id pub-id-type="pmid">30065350</pub-id><pub-id pub-id-type="pmcid">PMC6218396</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guilcher</surname><given-names>SJT</given-names></string-name>, <string-name name-style="western"><surname>Hogan</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>McCormack</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Calzavara</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hitzig</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Packer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lofters</surname><given-names>AK.</given-names></string-name></person-group><article-title>Prevalence of Prescribed Opioid Claims Among Persons With Traumatic Spinal Cord Injury in Ontario, Canada: A Population-Based Retrospective Cohort Study</article-title>. <source>Arch Phys Med Rehabil</source>. <year>2021</year>;<volume>102</volume>:<fpage>35</fpage>&#8211;<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.apmr.2020.06.020</pub-id>.<pub-id pub-id-type="pmid">32891422</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gupta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>McColl</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Guilcher</surname><given-names>SJT.</given-names></string-name></person-group><article-title>Prescription medication cost, insurance coverage, and cost-related nonadherence among people with spinal cord injury in Canada</article-title>. <source>Spinal Cord</source><year>2020</year>;<volume>58</volume>:<fpage>587</fpage>&#8211;<lpage>595</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41393-019-0406-x</pub-id>.<pub-id pub-id-type="pmid">31900410</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hatch</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Raad</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Suda</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Stroupe</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Hon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>BM.</given-names></string-name></person-group><article-title>Evaluating the Use of medicare part D in the veteran population with spinal cord injury/disorder</article-title>. <source>Arch Phys Med Rehabil</source><year>2018</year>;<volume>99</volume>:<fpage>1099</fpage>&#8211;<lpage>1107</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.apmr.2017.12.036</pub-id>.<pub-id pub-id-type="pmid">29425699</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heutink</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Post</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Wollaars</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>van Asbeck</surname><given-names>FW.</given-names></string-name></person-group><article-title>Chronic spinal cord injury pain: Pharmacological and non-pharmacological treatments and treatment effectiveness</article-title>. <source>Disabil Rehabil</source><year>2011</year>;<volume>33</volume>(<issue>5</issue>):<fpage>433</fpage>&#8211;<lpage>440</lpage>. doi:<pub-id pub-id-type="doi">10.3109/09638288.2010.498557</pub-id>.<pub-id pub-id-type="pmid">20695788</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hwang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zebracki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>LC.</given-names></string-name></person-group><article-title>Medication profile and polypharmacy in adults with pediatric-onset spinal cord injury</article-title>. <source>Spinal Cord</source><year>2015</year>;<volume>53</volume>:<fpage>673</fpage>&#8211;<lpage>678</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2015.62</pub-id>.<pub-id pub-id-type="pmid">25896344</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kokorelis</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez-Fernandez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sadowsky</surname><given-names>C.</given-names></string-name></person-group><article-title>Effects of drugs on bone metabolism in a cohort of individuals with traumatic spinal cord injury</article-title>. <source>Spinal Cord Ser Cases</source><year>2019</year>;<volume>5</volume>(<issue>3</issue>):<fpage>1</fpage>&#8211;<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41394-018-0146-8</pub-id>.<pub-id pub-id-type="pmcid">PMC6335409</pub-id><pub-id pub-id-type="pmid">30675387</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kratz</surname><given-names>ALF</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>J</given-names><suffix>3rd</suffix></string-name>, <string-name name-style="western"><surname>Kalpakjian</surname><given-names>CZ</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>P.</given-names></string-name></person-group><article-title>Medicate or meditate? Greater pain acceptance is related to lower pain medication Use in persons With chronic pain and spinal cord injury</article-title>. <source>Clin J Pain</source><year>2018</year>;<volume>34</volume>:<fpage>357</fpage>&#8211;<lpage>365</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ajp.0000000000000550</pub-id>.<pub-id pub-id-type="pmid">28877136</pub-id><pub-id pub-id-type="pmcid">PMC5835158</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mann</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schaefer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sadosky</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bergstrom</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Baik</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Parsons</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Nalamachu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stacey</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Tuchman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Anschel</surname><given-names>A</given-names></string-name></person-group>,<italic toggle="yes">, et al</italic>. <article-title>Burden of spinal cord injury-related neuropathic pain in the United States: Retrospective chart review and cross-sectional survey</article-title>. <source>Spinal Cord</source><year>2013</year>;<volume>51</volume>:<fpage>564</fpage>&#8211;<lpage>570</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2013.34</pub-id>.<pub-id pub-id-type="pmid">23588572</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Margolis</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Juneau</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sadosky</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cappelleri</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Bryce</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Nieshoff</surname><given-names>EC.</given-names></string-name></person-group><article-title>Health care utilization and expenditures among medicaid beneficiaries with neuropathic pain following spinal cord injury</article-title>. <source>J Pain Res</source><year>2014</year>;<volume>7</volume>:<fpage>379</fpage>&#8211;<lpage>387</lpage>. doi:<pub-id pub-id-type="doi">10.2147/jpr.S63796</pub-id>.<pub-id pub-id-type="pmid">25061337</pub-id><pub-id pub-id-type="pmcid">PMC4085322</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McCasland</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Budiman-Mak</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Miskevics</surname><given-names>S.</given-names></string-name></person-group><article-title>Shoulder pain in the traumatically injured spinal cord patient: Evaluation of risk factors and function</article-title>. <source>J Clin Rheumatol</source><year>2006</year>;<volume>12</volume>:<fpage>179</fpage>&#8211;<lpage>186</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.rhu.0000230532.54403.25</pub-id>.<pub-id pub-id-type="pmid">16891921</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nielsen</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Faaborg</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Christensen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Krogh</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Finnerup</surname><given-names>NB.</given-names></string-name></person-group><article-title>Chronic abdominal pain in long-term spinal cord injury: A follow-up study</article-title>. <source>Spinal Cord</source><year>2017</year>;<volume>55</volume>:<fpage>290</fpage>&#8211;<lpage>293</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2016.124</pub-id>.<pub-id pub-id-type="pmid">27502843</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>Norrbrink</given-names><surname>Budh C</surname></string-name>, <string-name name-style="western"><surname>Lund</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Hultling</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Levi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Werhagen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ertzgaard</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lundeberg</surname><given-names>T.</given-names></string-name></person-group><article-title>Gender related differences in pain in spinal cord injured individuals</article-title>. <source>Spinal Cord</source><year>2003</year>;<volume>41</volume>:<fpage>122</fpage>&#8211;<lpage>128</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sj.sc.3101407</pub-id>.<pub-id pub-id-type="pmid">12595876</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Norrbrink Budh</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lundeberg</surname><given-names>T.</given-names></string-name></person-group><article-title>Use of analgesic drugs in individuals with spinal cord injury</article-title>. <source>J Rehabil Med</source><year>2005</year>;<volume>37</volume>:<fpage>87</fpage>&#8211;<lpage>94</lpage>. doi:<pub-id pub-id-type="doi">10.1080/16501970410020455</pub-id>.<pub-id pub-id-type="pmid">15788343</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Milligan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>J.</given-names></string-name></person-group><article-title>Medication-related problems in individuals with spinal cord injury in a primary care-based clinic</article-title>. <source>J Spinal Cord Med</source><year>2017</year>;<volume>40</volume>:<fpage>54</fpage>&#8211;<lpage>61</lpage>. doi:<pub-id pub-id-type="doi">10.1179/2045772315Y.0000000055</pub-id>.<pub-id pub-id-type="pmid">26446538</pub-id><pub-id pub-id-type="pmcid">PMC5376141</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rouleau</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Guertin</surname><given-names>PA.</given-names></string-name></person-group><article-title>Traumatic and nontraumatic spinal-cord-injured patients in Quebec, Canada. Part 3: Pharmacological characteristics</article-title>. <source>Spinal Cord</source><year>2011</year>;<volume>49</volume>:<fpage>186</fpage>&#8211;<lpage>195</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2010.70</pub-id>.<pub-id pub-id-type="pmid">20548322</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsai</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Bryce</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Delgado</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Mulroy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Maclntyre</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Charlifue</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Felix</surname><given-names>ER.</given-names></string-name></person-group><article-title>Treatments that are perceived to be helpful for non-neuropathic pain after traumatic spinal cord injury: A multicenter cross-sectional survey</article-title>. <source>Spinal Cord</source><year>2021</year>;<volume>59</volume>:<fpage>520</fpage>&#8211;<lpage>528</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41393-021-00621-9</pub-id>.<pub-id pub-id-type="pmid">33742116</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Turner</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Cardenas</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Warms</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>McClellan</surname><given-names>CB.</given-names></string-name></person-group><article-title>Chronic pain associated with spinal cord injuries: A community survey</article-title>. <source>Arch Phys Med Rehabil</source><year>2001</year>;<volume>82</volume>:<fpage>501</fpage>&#8211;<lpage>508</lpage>. doi:<pub-id pub-id-type="doi">10.1053/apmr.2001.21855</pub-id>.<pub-id pub-id-type="pmid">11295011</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ullrich</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Blow</surname><given-names>FC</given-names></string-name>, <string-name name-style="western"><surname>Valenstein</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>FM.</given-names></string-name></person-group><article-title>Depression, healthcare utilization, and comorbid psychiatric disorders after spinal cord injury</article-title>. <source>J Spinal Cord Med</source><year>2014</year>;<volume>37</volume>:<fpage>40</fpage>&#8211;<lpage>45</lpage>. doi:<pub-id pub-id-type="doi">10.1179/2045772313Y.0000000137</pub-id>.<pub-id pub-id-type="pmid">24090156</pub-id><pub-id pub-id-type="pmcid">PMC4066550</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Warms</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Cardenas</surname><given-names>DD.</given-names></string-name></person-group><article-title>Treatments for chronic pain associated with spinal cord injuries: many are tried, few are helpful</article-title>. <source>Clin J Pain</source><year>2002</year>;<volume>18</volume>:<fpage>154</fpage>&#8211;<lpage>163</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00002508-200205000-00004</pub-id>.<pub-id pub-id-type="pmid">12048417</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Reinhardt</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Gosney</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Baumberger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J.</given-names></string-name></person-group><article-title>Spinal cord injury-related chronic pain in victims of the 2008 Sichuan earthquake: A prospective cohort study</article-title>. <source>Spinal Cord</source><year>2013</year>;<volume>51</volume>:<fpage>857</fpage>&#8211;<lpage>862</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2013.59</pub-id>.<pub-id pub-id-type="pmid">23817536</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Widerstr&#246;m-Noga</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Turk</surname><given-names>DC.</given-names></string-name></person-group><article-title>Types and effectiveness of treatments used by people with chronic pain associated with spinal cord injuries: influence of pain and psychosocial characteristics</article-title>. <source>Spinal Cord</source><year>2003</year>;<volume>41</volume>:<fpage>600</fpage>&#8211;<lpage>609</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sj.sc.3101511</pub-id>.<pub-id pub-id-type="pmid">14569261</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wilkinson</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Herrity</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dietz</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khattar</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nuno</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Drazin</surname><given-names>D</given-names></string-name></person-group>, <italic toggle="yes">et al</italic>. <article-title>Opioid dependence and associated health care utilization and cost in traumatic spinal cord injury population: analysis using marketscan database</article-title>. <source>Top Spinal Cord Inj Rehabil</source><year>2023</year>;<volume>29</volume>:<fpage>118</fpage>&#8211;<lpage>130</lpage>. doi:<pub-id pub-id-type="doi">10.46292/sci22-00026</pub-id>.<pub-id pub-id-type="pmid">36819927</pub-id><pub-id pub-id-type="pmcid">PMC9936895</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Graham</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Moran</surname><given-names>JL.</given-names></string-name></person-group><article-title>Robust meta-analytic conclusions mandate the provision of prediction intervals in meta-analysis summaries</article-title>. <source>J Clin Epidemiol</source><year>2012</year>;<volume>65</volume>:<fpage>503</fpage>&#8211;<lpage>510</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jclinepi.2011.09.012</pub-id>.<pub-id pub-id-type="pmid">22265586</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>DeVivo</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Biering-S&#248;rensen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>New</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></string-name></person-group><article-title>Standardization of data analysis and reporting of results from the international spinal cord injury core data set</article-title>. <source>Spinal Cord</source><year>2011</year>;<volume>49</volume>:<fpage>596</fpage>&#8211;<lpage>599</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2010.172</pub-id>.<pub-id pub-id-type="pmid">21135863</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jeng</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Meisel</surname><given-names>ZF</given-names></string-name>, <string-name name-style="western"><surname>Schackman</surname><given-names>BR.</given-names></string-name></person-group><article-title>Assessing the impact of state policies for prescription drug monitoring programs on high-risk opioid prescriptions</article-title>. <source>Health Aff (Millwood)</source><year>2018</year>;<volume>37</volume>:<fpage>1596</fpage>&#8211;<lpage>1599</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2018.0512</pub-id>.<pub-id pub-id-type="pmid">30273045</pub-id><pub-id pub-id-type="pmcid">PMC6362993</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Furlan</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Sandoval</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Mailis-Gagnon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tunks</surname><given-names>E.</given-names></string-name></person-group><article-title>Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects</article-title>. <source>CMAJ</source><year>2006</year>;<volume>174</volume>:<fpage>1589</fpage>&#8211;<lpage>1594</lpage>. doi:<pub-id pub-id-type="doi">10.1503/cmaj.051528</pub-id>.<pub-id pub-id-type="pmid">16717269</pub-id><pub-id pub-id-type="pmcid">PMC1459894</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wertheimer</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mathieson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Maher</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>C-WC</given-names></string-name>, <string-name name-style="western"><surname>McLachlan</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Buchbinder</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Underwood</surname><given-names>M.</given-names></string-name></person-group><article-title>The prevalence of opioid analgesic use in people with chronic noncancer pain: Systematic review and meta-analysis of observational studies</article-title>. <source>Pain Med</source><year>2020</year>;<volume>22</volume>:<fpage>506</fpage>&#8211;<lpage>517</lpage>. doi:<pub-id pub-id-type="doi">10.1093/pm/pnaa322</pub-id>.<pub-id pub-id-type="pmid">33164087</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Halvorsen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pettersen</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Nilsen</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Krizak Halle</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Elmenhorst Schaanning</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Rekand</surname><given-names>T.</given-names></string-name></person-group><article-title>Non-traumatic spinal cord injury in Norway 2012&#8211;2016: Analysis from a national registry and comparison with traumatic spinal cord injury</article-title>. <source>Spinal Cord</source><year>2019</year>;<volume>57</volume>:<fpage>324</fpage>&#8211;<lpage>330</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41393-018-0223-7</pub-id>.<pub-id pub-id-type="pmid">30552411</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>J.</given-names></string-name></person-group><article-title>Epidemiology of spinal cord injury: Changes to its cause amid aging population, a single center study</article-title>. <source>Ann Rehabil Med</source><year>2021</year>;<volume>45</volume>:<fpage>7</fpage>&#8211;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.5535/arm.20148</pub-id>.<pub-id pub-id-type="pmid">33557481</pub-id><pub-id pub-id-type="pmcid">PMC7960948</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>New</surname><given-names>PW</given-names></string-name>, <string-name name-style="western"><surname>Simmonds</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Stevermuer</surname><given-names>T.</given-names></string-name></person-group><article-title>A population-based study comparing traumatic spinal cord injury and non-traumatic spinal cord injury using a national rehabilitation database</article-title>. <source>Spinal Cord</source><year>2011</year>;<volume>49</volume>:<fpage>397</fpage>&#8211;<lpage>403</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sc.2010.77</pub-id>.<pub-id pub-id-type="pmid">20603631</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>